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1. INTRODUCTION 
Congenital disorders of glycosylation (CDG) are an expanding group of in-
herited metabolic diseases caused by primary hypoglycosylation of proteins and 
lipids. Glycosylation is a process in which monosaccharides are attached to an 
acceptor molecule. It occurs in every cell, and it is very important for normal 
functioning of many circulating, membranous and intracellular proteins. CDG 
was first presented as a new syndrome in identical twin sisters by Jaeken and 
colleagues in 1980 (Jaeken et al 1980). Fifteen years later, decreased activity of 
phosphomannomutase 2 (PMM2) was described as a cause of CDG type I (Van 
Schaftingen and Jaeken 1995), which is now named as PMM2-CDG, and 
known as the most frequently diagnosed CDG worldwide.  
 Since 1980, over 125 types of CDG have been identified. Overall, about 
~2% of all genes in the human genome are considered to be involved in glyco-
sylation (Ng and Freeze 2018). Most of CDG are inherited in autosomal 
recessive pattern, fewer are autosomal dominant or X-linked disorders (Jaeken 
and Peanne 2017; Ng and Freeze 2018). Earlier, the patients were classified 
either as having CDG-I or CDG-II depending on the pattern found with the 
serum transferrin (Tf) isoelectric focusing (IEF), a method used frequently for 
CDG screening. Small Latin letters indicated the order in which disorders were 
discovered (e.g. CDG-Ia, CDG-Ib). Since 2009, new nomenclature is in use 
where official gene symbol is followed by ’-CDG’, as this disease group does 
not only include disorders of protein N- and O-glycosylation, but also glyco-
sylation defects in glycosphingolipid and glycosylphosphatidylinositol (GPI) 
anchor pathways as well as in multiple glycosylation and other pathways 
(Jaeken et al 2008; Jaeken et al 2009). Nevertheless, disorders in the N-glyco-
sylation pathway are most common, and according to the data from twelve 
laboratories in Europe, 94% of molecularly confirmed patients had CDG-I and 
6% had CDG-II (Peanne et al 2017).  
 The synthesis of N-glycans is complex and involves many enzymes. 
Variants in genes can severely reduce the activity of different enzymes (e.g. 
glycosyltransferases, glycosidases) or impair the function of other proteins im-
portant in the glycosylation pathway (e.g. transporters), which ultimately lead to 
defective synthesis of glycoproteins. Also, the cellular environment and 
homeostasis are important for the correct glycosylation and any deviation can 
influence this process.  
 The clinical presentation and severity of different CDG is wide and often un-
specific. It can be multisystem disease and/or involve only the nervous system. 
It is emphasized that CDG should be considered and screened in every patient 
with unexplained neurological symptoms, especially if accompanied by multi-
organ abnormalities. Tf IEF still remains the main screening method for CDG. 
As screening with Tf IEF can only be positive with disorders that affect N-
glycosylation, negative results are present in more than half of different CDG 
(Jaeken and Peanne 2017). In addition, several types of CDG with usual 
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positive screening can show age-dependent false-negative results with Tf IEF. 
Therefore, the diagnostics for CDG can be challenging. In earlier days, different 
CDG were confirmed with biochemical studies when possible, and/or single 
gene sequencing. Nowadays it is not unusual that more and more patients are 
diagnosed with CDG with different next-generation sequencing (NGS) tech-
niques that have helped to solve suspected, or discover novel CDG. This has in 
turn raised the question whether all suspected variants are pathogenic and in-
fluence glycosylation, and it stresses the importance of functional assays (Ng 
and Freeze 2018).  
 In 2007/2008, the first patient with PMM2-CDG was diagnosed in Estonia 
(Vals et al 2014). The male newborn presented with multisystem disease and 
peculiar phenotype, and died on the 6th day of life. His serum and skin fibro-
blasts were collected and sent to metabolic laboratory of Amsterdam Free Uni-
versity Medical Center in the Netherlands. His serum Tf IEF and enzymatic 
analyses referred PMM2-CDG, which was later molecularly confirmed. It was 
naive to believe that this newborn was the only CDG patient in Estonia. Un-
fortunately, before 2012 the screening of CDG was limited to a very small 
group of patients as the serum Tf IEF was done in foreign laboratories. This 
made the diagnostic methods for CDG less available and may have been one 
reason why this disorder was under-diagnosed.  
 The aim of this study was to implement Tf IEF in clinical practice and to 
study the occurrence of N-glycosylation defects among Estonian patients in a 
three-year screening period. Positive findings were followed by a study about 
the prevalence of the most common CDG type, PMM2-CDG, in Estonian 
population, and the characterization of Estonian patients with PMM2-CDG. In 
addition, two other types of CDG detected with Tf IEF during the study period 
will be described. First, a phenotype of SLC35A2-CDG is characterized based 
on the international cohort of patients (including Estonian patient), and 
secondly, an overview of a new, previously undescribed CDG possibly caused 
by homozygous variant in STX5 gene is given. 
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2. LITERATURE REVIEW 
2.1. N-glycosylation 
2.1.1. Synthesis of N-glycans  
N-glycosylation involves three main stages: formation of nucleotide-linked su-
gars, assembly, and processing of oligosaccharide. The synthesis takes place in 
cytosol, endoplasmic reticulum (ER) and in the Golgi, and requires many enzy-
mes. In addition to N-glycosylation specific enzymes, many other proteins and 
complexes are needed for N-glycan synthesis. The latter influence the normal 
course of N-glycosylation but also other pathways (e.g. protein O-glycosylation). 
Therefore, it is important to include these proteins in this overview as well. 
 In Figures 1 and 2, the illustration of N-glycosylation pathway is given to 
follow the metabolic steps described in this paragraph.  
 
 
2.1.1.1. Dolichol-phosphate synthesis 
Defects in dolichol (Dol) synthesis and metabolism are classified under the 
defects in multiple glycosylation and other pathways (Jaeken et al 2009; Morava 
and Lefeber 2011) but they carry also an important role in N-glycosylation.  
Dol is an alpha-saturated polyisoprenoid alcohol and a membrane lipid like 
component. De novo biosynthesis of Dol occurs in cytoplasmic side of ER. The first 
steps of Dol synthesis are common with cholesterol synthesis. Its intermediate 
product farnesyl pyrophosphate is elongated with molecules of isopentenyl 
pyrophosphate by dehydrodolichyl diphosphate synthase (DHDDS) and Nogo-B 
receptor (NUS1) complex and subsequently, polyprenol pyrophosphate is synthe-
sized. Polyprenol pyrophosphate is dephosphorylated into polyprenol and sub-
sequently reduced to Dol by steroid 5-α-reductase 3 (SRD5A3). Finally, Dol is 
phosphorylated (Dol-P) by dolichol kinase (DOLK) (Figure 3).  
In N-glycosylation process, Dol-P acts as a lipid carrier for oligosaccharide. 
In addition to de novo biosynthesis, Dol can be re-used after oligosaccharide 
transfer from Dol onto protein (Chapter 2.1.1.4.). Dol-P-P is dephosphorylated 
into Dol-P, which returns to the cytoplasmic side of ER. 
Dol-P also serves as a glucose (Glu) and mannose (Man) donor (Dol-P-Glu 
and Dol-P-Man respectively) in ER, after lipid-linked oligosaccharide (LLO) is 
flipped in the lumen of ER. Four Dol-P linked to a Man (enzymes dolichol-
phosphate mannosyltransferase subunits 1, 2 and 3; DPM1, DPM2, DPM3 
respectively) and three Dol-P linked to a Glu are also flipped in the lumen of 
ER, and serve as sugar carriers for further LLO elongation. The mannose-P-
dolichol utilization defect 1 protein (MPDU1) locates in ER and is needed for 
bioavailability and utilization of Dol-P-Man and Dol-P-Glu. 
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Figure 3. Schematic overview of de novo biosynthesis of dolichol phosphate from the 
intermediate farnesyl pyrophosphate. 
 
 
The lack of end product Dol-P leaves glycoproteins with unoccupied N-glyco-
sylation sites and causes reduction of glycosylation in case of SRD5A3 and 
DOLK deficiency. With the deficiency of DHDDS and MPDU1, truncated 
LLOs are characteristic.  
As Dol-P is needed as a Man donor also in O-glycosylation and GPI-anchor 
synthesis, these processes are affected, when defects are present (Marquardt and 
Denecke 2003; Cantagrel and Lefeber 2011). 
 
 
2.1.1.2. Synthesis of nucleotide-linked sugars 
Monosaccharides act as substrates in the process of N-glycosylation and are 
synthesized and activated in the cytoplasmic side of ER by guanosine dipho-
sphate (GDP) or uridine diphosphate (UDP), or in nucleus by cytidine mono-
phosphate (CMP). Following sugars are needed in the N-glyosylation process: 
Man, Glu, N-acetylglucoseamine (GlcNAc), fucose (Fuc), galactose (Gal), and 
sialic acid (Sia). They are transferred and attached to oligosaccharide in the 
form of activated nucleotide-linked sugars (GDP-Man, UDP-Glu, UDP-
GlcNAc, GDP-Fuc, UDP-Gal and CMP-Sia). Activated nucleotide-linked 
sugars can only be used in the cytosolic side of ER and ER membrane is im-
permeable for them. In the ER lumen and the Golgi, Dol-P and special transpor-
ters are used to deliver monosaccharides in the continuing synthesis of glycan. 
Monosaccharides mostly originate from dietary sources. Man is synthesized 
from fructose-6-phosphate with enzymes mannose-6-phosphate isomerase 
(MPI) and phospohomannomutase 2 (PMM2, Figure 4). Activated nucleotid-
Farnesyl pyrophosphate 
 
 
Polyprenol pyrophosphate 
  
 
 
                    Polyprenol 
 
 
 
 
           Dolichol phosphate 
                      DHDDS; NUS1 
                   Dolichol 
        SRD5A3 
        DOLK 
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linked sugar GDP-Man is synthesized from mannose-1-phosphate and 
guanosine triphosphate by guanosine diphosphate mannose pyrophosphorylase 
A and B (GMPPA and GMPPB respectively). Two important types of CDG are 
caused by Man deficiency, PMM2-CDG and MPI-CDG (Marquardt and 
Denecke 2003; Sparks 2012; Jaeken and Peanne 2017). 
 
 
 
Figure 4. GDP-mannose synthesis. 
 
For UDP-Glu synthesis, normal activity of phosphoglucomutase 1 (PGM1) is 
important, since its deficit causes lack of glucose-1-phosphate, the precursor of 
UDP-Glu. PGM1 is also an important enzyme in glycolysis and glyconeo-
genesis, and its deficiency causes different phenotypes: glycogen storage 
disease XIV with muscle involvement, and hypoglycosylation of proteins with 
multisystem presentation (Morava 2014).  
 
 
2.1.1.3. Dolichol-linked oligosaccharide biosynthesis 
Biosynthesis of LLO starts in the cytoplasmic ER membrane where Dol-P acts 
as a lipid carrier (Figure 1). In the cytoplasmic side, the process uses activated 
nucleotide linked sugars. First, GlcNAc-1-phosphate is linked to Dol-P by 
dolichyl-phosphate N-acetylglucoseamine phosphotransferase (DPAGT1). 
UDP-GlcNAc transferase (ALG13/ALG14) adds the second GlcNAc. GlcNAc2-
PP-Dol is elongated by different mannosyltransferases (ALG1, ALG2 and 
ALG11), and altogether five molecules of Man are added. After the attachment 
of first Man, oligosaccharide branches into two arms (α1,3 and α1,6) and α1,3 
arm is extended by two additional Man.  
Biantennary structure Man5-GlcNAc2-PP-Dol is translocated from the 
cytoplasmic side of ER to the luminal side by flippase (including its accessory 
 Glucose 
 
 
 
 
 
              GTP      
            GMPPA 
          GMPPB 
 
MPI 
PMM2 
Fructose-6-phosphate    Mannose-6-phosphate 
       Mannose-1-phosphate 
         GDP-Man 
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unit RNA polymerase-associated protein, RFT1). Now, only Dol-P-Man and 
Dol-P-Glu can be used as monosaccharide carriers for the further elongation of 
translocated oligosaccharide. Four additional mannoses are added by ER-
localized mannosyltransferases (ALG3, ALG9, ALG12) and additional 
α1,3/α1,6 branch is generated to a branch α1,6. Finally, three glycoses are added 
to the first α1,3 arm by glycosyltransferases (ALG6, ALG8) and the final 
structure of oligosaccharide Glu3-Man9-GlcNAc2-PP-Dol is ready. In the 
assembly stage, twelve different types of CDG have been described (Chapter 
2.1.3.3.) (Marquardt and Denecke 2003; Jaeken 2010; Stanley et al 2015). 
 
 
2.1.1.4. Transfer of oligosaccharide 
At the luminal side of ER, an assembled LLO (Glu3-Man9-GlcNAc2-PP-Dol) is 
removed from its lipid carrier and attached to the protein by oligosaccharyl 
transferase complex (OST, Figure 1). The transfer occurs during or after the 
translocation of the protein. N-glycosylation uses the amide group of amino 
acid asparagine (Asn) for binding to the protein. It is important that Asn should 
be located within Asn-Xxx-serine (Ser)/threonine (Thr) sequence and Xxx 
cannot be proline (Pro). OST has high substrate affinity and carries mostly fully 
assembled oligosaccharides. Incomplete oligosaccharides reduce the transfer 
efficiency and cause hypoglycosylation with empty N-glycan sites. Four types 
of CDG are known to have been caused by defective OST subunits (DDOST, 
STT3A, STT3B, TUSC3) (Marquardt and Denecke 2003; Stanley et al 2015). 
 
 
2.1.1.5. Processing of protein-bound oligosaccharide 
After oligosaccharide transfer, three Glu and one Man (branch α1,6) are trim-
med by glucosidases (MOGS, GANAB, PRKCSH) and mannosyl-oligo-
saccharide alpha-1,2-mannosidase (MAN1B1). The process takes place in the 
luminal side of ER and in the Golgi (Figure 1 and 2). During trimming, protein 
quality control is performed, which determines whether glycoprotein will be 
degraded or processing will continue. 
The Golgi has cisternal organization, which ensures the sequential process 
on N-glycosylation. Each enzyme and transporter localizes in cisternae where it 
needs to be active either by catalyzing the reaction or transporting the mono-
saccharides. Cisternae also help to create appropriate optimal microenvironment 
for enzymes (Reynders et al 2011). The essential substrates CMP-Sia, UDP-
Gal, UDP-GlcNAc and GDP-Fuc are provided by the respective transporters 
(SLC35A1, SLC35A2, SLC35A3 and SLC35C1, respectively), which are im-
portant also in other glycosylation pathways. 
In the cis-Golgi, additional three Man are removed from protein-bound 
Man8-GlcNAc2 by mannosidases, creating Man5-GlcNAc2 intermediate, which 
is a key intermediate. In the medial Golgi, GlcNAc is added by GlcNAc-trans-
ferase I to the branch α1,3. Then two other Man are removed leaving three Man 
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core. The second GlcNAc is added to the other arm by beta-1,2-N-acetylgluco-
saminyltransferase II (MGAT2) and biantennary glycan is formed. Next, in the 
trans-Golgi, two Gal are added to both antenna of GlcNAc2-Man3-GlcNAc2 by 
beta-1,4-galactosyltransferase 1 (B4GALT1). Finally, two Sia residues are 
added by sialyltransferase and the final glycan Sia2-Gal2-GlcNAc2-Man3-
GlcNAc2 is ready. Glycoprotein is secreted, moved to the plasma membrane or 
lysosomes.  
In addition to the described formation of biantennary glycans, some synthe-
sized glycoproteins are also fucosylated  (e.g. ABO blood group antigens) or 
have more than two branches in their glycan structure as a result of the activity 
of different GlcNAc-transferases (e.g. α-1-antitrypsin) (Marquardt and Denecke 
2003; Caramelo and Parodi 2007; Rymen et al 2013; Stanley et al 2015).  
 
2.1.1.6. Other proteins affecting N-glycosylation 
As mentioned at the beginning of the chapter, many other proteins are involved 
in the process of N-glycosylation. They are important in multiple glycosylation 
pathways and some of them were previously described (e.g. Dol synthesis, 
monosaccharide transporters). In addition, vacuolar H+-ATPase complex 
subunits ATP6AP1 (localized in ER and ER-Golgi Intermediate Compartment, 
ERGIC) and ATP6V0A2 (localized in Golgi) are important for acidification of 
intracellular compartments and regulate Golgi pH, which is essential for the 
activity of glycosyltransferases. Conserved oligomeric Golgi (COG) complex is 
important in retrograde trafficking of vesicles from Golgi to ER as well as intra-
Golgi to maintain the proper localization of different resident proteins, in-
cluding enzymes needed for glycosylation in the Golgi. COG complex includes 
eight subunits and defects are described in all, except in subunit COG3. 
Subunits COG1-4 are organized in lobe A and subunits GOG5-8 in lobe B. 
Subunits COG1 and COG8 interact two lobes. Defect in one subunit destabi-
lizes other subunits, reduces their expression and association with the Golgi. 
GOG defects lead to mislocalization and decreased activity of glycosyltrans-
ferases such as mannosidase II and B4GALT1 as well as Golgi transporters, 
which disturb the normal process of glycosylation (Reynders et al 2011). 
 Coiled-coil domain containing protein 115 (CCDC115) and transmembrane 
protein 199 (TMEM199) locate in ERGIC and play a role in Golgi homeostasis 
(Jansen et al 2016a; Jansen et al 2016b). Manganese and zinc transporter 
(SLC39A8) is a membrane protein important for uptake of manganese, zinc and 
other cations into cell, and probably thereby affects the affinity of galacto-
syltransferase to UDP-Gal. In conclusion, all these proteins help to provide a 
proper environment and trafficking in Golgi, which is important for the function 
of different enzymes (Smith and Lupashin 2008; Park et al 2015; Jaeken and 
Peanne 2017). 
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2.1.2. Screening of N-glycosylation defects 
The standard screening test for N-glygosylation disorders is serum Tf IEF 
(Jaeken and Peanne 2017). Serum Tf is rather simple N-glycosylated glyco-
protein, which has only two Asn with appropriate motif. Therefore, Tf carries 
two biantennary glycans with four Sia, and normally, the most prevalent band is 
tetrasialotransferrin. Small amounts of mono-, di-, tri-, penta- and hexasialo-
transferrins are present.  
Tf IEF separates Tf isoforms on the basis of their charge. As Sia is located 
on the top of biantennary glycan, and is negatively charged, its partial deficien-
cy causes the loss of negative charge, which leads to the change of Tf isoelectric 
point, and a cathodal shift in IEF. In case of type 1 pattern, decreased tetrasialo-
transferrin together with increased disialo- and asialotransferrin are seen. It 
refers to CDG-I defects (Table 1, Figure 5), where the supply of substrates, the 
synthesis of lipid carrier Dol-P, the assembly of the LLO or its transfer to the 
peptide chain is disturbed, and only one or none of the glycans are built. Thirty 
types of CDG show type 1 pattern in screening (Peanne et al 2017). 
In type 2 pattern, increased trisialo- and monosialotransferrin are also pre-
sent in addition to disialo- and asialotransferrin bands. Tetrasialotransferrin can 
be normal or reduced. This refers to CDG-II defects (Table 1, Figure 5), where 
the processing of protein-bound glycans is disturbed and they are structurally 
abnormal. At least 18 types of CDG show type 2 pattern in the screening 
(Peanne et al 2017). 
Normal Tf IEF does not exclude CDG. First, some types of CDG always 
show normal sialotransferrins (e.g. MOGS-CDG, GANAB-CDG, PRKCSH-
CDG, SLC35A3-CDG, SLC35C1-CDG), and second, some types may show 
both, normal and abnormal pattern in Tf IEF (e.g. SRD35A3-CDG, ALG13-
CDG, SLC35A2-CDG). Third, the results can be influenced by age. For 
instance, false-negative results have been described in adolescents and adults. 
On the contrary, up to 6 weeks of age, mild type 2 pattern, caused by hypo-
sialylated Tf, might be present, and all the Tf bands appear slightly more intense 
than usual (false-positive). One possibility is to do in parallel an α-1-antitrypsin 
IEF in early infancy to evaluate the possible diagnosis of CDG (Thiel et al 
2013). α-1-antitrypsin has three N-glycosylation sites to which bi-, tri- and 
tetraantennary glycans are attached (Barone et al 2008). Another possibility is 
to repeat Tf IEF in later infancy. 
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Table 1. Different types of CDG with positive Tf IEF (according to Jaeken and Peanne 
2017, Peanne et al 2017 and Ferreira et al 2018).  
 
 Tf IEF   
CDG Type 1  Type 2  Comments 
DDOST-CDG +   
DHDDS-CDG  +  Normal Tf IEF has been reported 
DPM1-CDG +   
DPM2-CDG +   
DPM3-CDG +   
DOLK-CDG +   
DPAGT1-CDG +   
ALG1-CDG +   
ALG2-CDG +   
ALG3-CDG +   
ALG6-CDG +   
ALG8-CDG +   
ALG9-CDG +   
ALG11-CDG +   
ALG12-CDG +   
ALG13-CDG +  Normal Tf IEF has been reported 
ALG14-CDG +  Normal Tf IEF has been reported 
MPDU1-CDG +   
MPI-CDG +   
NUS1-CDG +   
PMM2-CDG +  Normal Tf IEF has been reported 
RFT1-CDG +   
SRD5A3-CDG +  Normal Tf IEF has been reported 
STT3A-CDG +   
STT3B-CDG +   
TUSC3-CDG +   
PGM1-CDG + +          Mixed type 1 and 2 profile 
ATP6AP1-CDG  +  
ATP6V0A2-CDG  +  
BGALT1-CDG  +  
CCDC115-CDG  +  
COG1-CDG  +  
COG2-CDG  +  
COG4-CDG  +  
COG5-CDG  +  
COG6-CDG  +  
COG7-CDG  +  
COG8-CDG  +  
MAN1B1-CDG  +  
MGAT2-CDG  +  
SLC35A1-CDG  +     Normal Tf IEF has been reported 
SLC35A2-CDG  + Normal Tf IEF has been reported 
SLC39A8-CDG  +  
TMEM199-CDG  +  
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  Figure 5. Different profiles in Tf IEF. The arrows are indicating the number of sialic 
acid residues. The samples originate from ERNDIM (European Research Network for 
evaluation and improvement of screening, Diagnosis and treatment of Inherited 
disorders of Metabolism) Quality Control scheme for CDG screening 2018 (with the 
permission of Dirk Lefeber). 
 
 
False-positive results can be also seen with diseases where secondary hypo-
glycosylation might be present (galactosemia, hereditary fructose intolerance, 
alcohol abuse, infections with neuraminidase-producing organism, and liver 
pathology). Tf polymorphisms can also cause a change of Tf isoelectric point 
and show abnormal pattern in IEF. Polymorphism should be excluded with 
neuraminidase digestion, which reduces all glycoforms into two asialotrans-
ferrins. Still, if Tf polymorphism is caused by a variant in the Asn-Xxx-Ser/Thr 
sequence leading to Tf with a single glycan, the treatment with neuraminidase 
can be misleading. Comparative Tf IEF from the serum of the parents or 
alternative glycoprotein IEF can be helpful then (Guillard et al 2011). 
In addition to Tf and α-1-antitrypsin IEF, other serum proteins like 
thyroxine-binding globuline can be screened for CDG. In case of patients with 
type 2 Tf IEF, diagnostics should proceed with mass spectrometry (MS, Chapter 
2.1.4.2.) and serum apolipoprotein C-III (ApoC-III) IEF after inconclusive MS 
result. ApoC-III is a marker of mucin type core 1 O-glycan synthesis and 
abnormalities detected with IEF refer to combined N- and O-glycosylation 
defect (e.g. COG-associated CDG). ApoC-III shows three isoforms in IEF 
depending on the number of Sia residues attached to only one core 1 mucin-type 
O-glygan: ApoC-III0 (nonglycosylated), ApoC-III1 and ApoC-III2 (normally, a 
major isoform) (Wopereis et al 2003; Lefeber et al 2011). 
Alternative approaches for screening of N-glycosylation defects are capillary 
zone electrophoresis and high-pressure liquid chromatography, which also 
separate Tf isoforms based on their charge. These methods are more rapid and 
results are easily quantified (Quintana et al 2009; Parente et al 2010; Jaeken and 
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Peanne 2017). Still, serum Tf IEF is advised, when abnormal results are seen 
(Quintana et al 2009; Parente et al 2010; Jaeken and Peanne 2017). 
A new potential biomarker for detecting hypoglycosylation in CDG type 1 is 
a plasma membrane glycoprotein called intercellular cell adhesion molecule 1 
(ICAM-1). Its expression is shown to be reduced or absent in plasma 
membranes of glycosylation-deficient cells. In addition, ICAM-1 can be used to 
follow therapeutic response in different types of CDG where potential thera-
peutics are possible. In case of MPI-CDG, Man supplementation to MPI-defi-
cient cells increased ICAM-1 expression (He et al 2012). 
 
 
2.1.3. Overview of clinical features of different CDG 
In this chapter an overview of the clinical phenotypes of selected CDG with or 
without positive screening caused by impaired N-glycan synthesis is given 
(Table 1). In many types of CDG, very few patients have been described. The 
symptoms are often variable, overlapping and unspecific, and may not lead to 
clinical suspicion of CDG. The severity of a phenotype might differ between 
different types of CDG as well as in patients with the same CDG type. The 
nervous system is almost always affected. Currently, the majority of CDG do 
not have effective treatment. 
Recently, a comprehensive scheme based on sialotransferrin profile and 
clinical symptoms was published to narrow the selection of the possible candi-
date CDG, which could help shorten the time period from clinical suspicion to 
genetic confirmation of CDG (Perez-Cerda et al 2017). Once the diagnosis is 
confirmed, the disease course can be objectively monitored with Nijmegen 
CDG rating scale. Its sections include parental or a caretaker’s evaluation for 
current function, a clinician’s evaluation of systems involved, and present 
clinical assessment (Achouitar et al 2011).  
 
2.1.3.1. Defects in dolichol synthesis and metabolism 
Variants in genes DHDDS, NUS1, SRD5A3 and DOLK cause DHDDS-CDG, 
NUS1-CDG (described only in one family), SRD5A3-CDG, and DOLK-CDG 
respectively. DHDDS-CDG (OMIM 613861) has been related to retinal 
involvement (retinitis pigmentosa) but at least one patient with multisystem pre-
sentation and protein hypoglycosylation has been reported (Zuchner et al 2011; 
Sabry et al 2016). SRD5A3-CDG (CDG-Iq, OMIM 612379) symptoms include 
developmental delay/intellectual disability (DD/ID), hypotonia, visual impair-
ment (optic nerve atrophy, cataract, glaucoma), cerebellar atrophy, dilated 
cardiomyopathy, ichthyosiform dermatitis, hepatic dysfunction, and coagulation 
abnormalities (Cantagrel et al 2010). DOLK-CDG (CDG-Im, OMIM 610768) 
causes DD/ID, epilepsy, hypsarrhythmia in EEG, hypotonia, nystagmus, dilated 
cardiomyopathy, and ichthyosis (Kranz et al 2007). In all four types, serum Tf 
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IEF shows type 1 pattern, although in adult with SRD5A3-CDG, a normal 
pattern was described (Cantagrel and Lefeber 2011; Kahrizi et al 2011; Moha-
med et al 2011; Jaeken and Peanne 2017; Peanne et al 2017). 
 Variants in genes MPDU1, DPM1, DPM2 and DPM3 cause MPDU1-CDG, 
DPM1-CDG, DPM2-CDG, and DPM3-CDG. MPDU1-CDG (CDG-If, OMIM 
609180), DPM1-CDG (CDG-Ie, OMIM 608799) and DPM2-CDG (CDG-Iu, 
OMIM 615042) symptoms include DD/ID, epilepsy, ataxia, and ophthalmo-
logical symptoms including visual loss. In addition, MPDU1-CDG causes 
dwarfism, ichthyosiform skin, and DPM1- and DPM2-CDG muscular dystrop-
hy with elevated creatine kinase level (Imbach et al 2000; Kranz et al 2001; 
Schenk et al 2001; Barone et al 2012). In DPM3-CDG (CDG-Io, OMIM 
612937) elevated creatine kinase level, muscle dystrophy and dilated cardio-
myopathy are seen (Lefeber et al 2009). Serum Tf IEF shows type 1 pattern in 
all four CDG (Cantagrel and Lefeber 2011; Peanne et al 2017). 
 
2.1.3.2. Defects in monosaccharide synthesis 
MPI-CDG (CDG-Ib, OMIM 602579) is caused by the deficiency of mannose-6-
phosphate isomerase (Niehues et al 1998). It used to be the third most common 
CDG but now few other CDG types are more frequently diagnosed. Symptoms 
arise mainly from gastrointestinal system and include congenital hepatic fibro-
sis, steatosis, cirrhosis, secretory diarrhea and protein-losing enteropathy, 
gastrointestinal bleeding, vomiting, failure to thrive, bleeding, thrombosis, and 
hyperinsulinemic hypoglycemia. The nervous system is usually spared unless 
complications like hypoglycemia occur. Serum Tf IEF shows type 1 pattern. 
MPI-CDG is treatable with oral mannose, as Man-6-phosphate can be alterna-
tively synthesized directly from Man by enzyme hexokinase. The treatment im-
proves gastrointestinal symptoms, hypoglycemia, coagulopathy and growth. 
Alternatively, heparin can be used. Man does not prevent the progression of 
liver disease and sometimes liver transplantation is needed. After transplanta-
tion, normal glycosylation of transferrin has been described as well as the 
improvement of coagulopathy and gastrointestinal symptoms. The glycosylation 
of non-liver-glycosylated proteins remained unchanged (de Koning et al 1998; 
de Lonlay et al 2001; de Lonlay and Seta 2009; Janssen et al 2014). 
 PGM1-CDG (CDG-It, OMIM 614921) symptoms include muscle weakness, 
dilated cardiomyopathy, chronic hepatitis, endocrine anomalies (hypogonado-
tropic hypogonadism), rhabdomyolysis, and dysmorphic features (Pierre-Robin 
sequence). Patients have normal intelligence, as PGM1 is not expressed in the 
nervous system (Stojkovic et al 2009; Timal et al 2012). PGM1 deficiency also 
affects Gal metabolism. UDP-Glu and UDP-Gal are in metabolic balance, which 
is supported by the epimerization of UDP-Gal to UDP-Glu. PGM1 deficiency 
leads to the reduced amounts of UDP-Gal, which causes decreased galacto-
sylation of glycans. Treatment with oral galactose is possible and improves 
glycosylation as well as symptoms, except dilated cardiomyopathy. Serum Tf IEF 
shows mixed type 1 and type 2 pattern (Timal et al 2012; Morava 2014). 
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PMM2-CDG (CDG-Ia, OMIM 212065) will be thoroughly discussed in 
Chapter 2.2. GMPPA-CDG (OMIM 615510) and GMPPB-CDG (OMIM 
615350) affect multiple glycosylation pathways (Carss et al 2013; Koehler et al 
2013). They do not show abnormal Tf IEF pattern and will not be described. 
 
 
2.1.3.3. Defects in the assembly of lipid-linked oligosaccharide 
DPAGT1-CDG (CDG-Ij, OMIM 608093) symptoms include progressive micro-
cephaly, epilepsy, hypotonia, cerebral atrophy, ophthalmological symptoms, jaun-
dice, dysmorphic features, joint contractures, and myasthenia (Wu et al 2003). In 
adolescents, normal Tf IEF pattern is possible. Improvement of myasthenia with 
cholinesterase inhibitor pyridostigmine has been described (Klein et al 2015; 
Peanne et al 2017). 
ALG13-CDG (CDG-Is, OMIM 300884) causes early infantile epileptic 
encephalopathy and ALG14-CDG (OMIM 616227) congenital myasthenia 
(Timal et al 2012; Cossins et al 2013). ALG1-CDG (CDG-Ik, OMIM 608540) 
symptoms include DD/ID, refractory epilepsy, hypotonia, cerebral atrophy, 
hepatosplenomegaly, dysmorphic features and hypogonadism (Schwarz et al 
2004). ALG2-CDG (CDG-Ii, OMIM 607906) symptoms are DD/ID, epilepsy, 
cataract, and hepatomegaly (Thiel et al 2013). ALG11-CDG (CDG-Ip, OMIM 
613661) causes DD/ID, epilepsy, hypotonia, deafness, ophthalmological symp-
toms, opisthotonus, dysmorphic features, feeding difficulties, and vomiting (Rind 
et al 2010).  
RFT1-CDG (CDG-In, OMIM 612015) symptoms include DD/ID, hypotonia, 
hyperreflexia, early-onset epilepsy, decreased visual acuity, dysmorphic featu-
res, sensorineural deafness, and short stature (Haeuptle et al 2008).  
ALG3-CDG (CDG-Id, OMIM 601110) symptoms are DD/ID, axial hypo-
tonia, hyperreflexia, epilepsy, cerebellar and corpus callosum hypoplasia, optic 
atrophy, cortical blindness, arthrogryposis, clubfeet, dysmorphic features, fai-
lure to thrive, vomiting, and diarrhea (Korner et al 1999). ALG9-CDG (CDG-
IL, OMIM 608776) patients have DD/ID, hypotonia, epilepsy, microcephaly, 
diffuse brain atrophy with delayed myelination, pericardial effusion, hepato-
splenomegaly, cystic renal disease, and failure to thrive (Frank et al 2004). 
ALG12-CDG (CDG-Ig, OMIM 607143) symptoms include DD/ID, hypotonia, 
microcephaly, widening of the lateral ventricles, blindness, cardiomyopathy, 
skeletal anomalies and delayed ossification, dysmorphic features, immuno-
deficiency with recurrent infections, and deafness (Chantret et al 2002).  
ALG6-CDG (CDG-Ic, OMIM 603147) is the second most common CDG. 
Symptoms include DD/ID, epilepsy, cortical blindness, ataxia, intention tremor, 
agenesis of corpus callosum, ophthalmological symptoms, distal limb defects, 
brachydactyly, endocrine as well as gastrointestinal disturbances (Burda et al 
1998; Imbach et al 1999). ALG8-CDG (CDG-Ih, OMIM 608104) causes ID, 
structural heart defects, hepatomegaly, cystic bile ducts, cholestasis, diffuse renal 
microcysts, dysmorphic features, protein-losing enteropathy, vomiting, 
brachydactyly, and skeletal anomalies (Chantret et al 2003).  
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All twelve CDG show type 1 pattern in Tf IEF and are autosomal recessive 
diseases except ALG13-CDG, which is X-linked disorder (Peanne et al 2017). 
 
 
2.1.3.4. Defects related to oligosaccharide transfer 
TUSC3-CDG (OMIM 611093), DDOST-CDG (CDG-Ir, OMIM 614507), 
STT3A-CDG (CDG-Iw, OMIM 615596) and STT3B-CDG (CDG-Ix, 615597) 
are OST subunits and cause similar symptoms like DD/ID, hypotonia, epilepsy, 
ophthalmological symptoms, and failure to thrive. Serum Tf IEF shows type 1 
pattern in all (Peanne et al 2017). 
 
 
2.1.3.5. Defects related to protein-bound oligosaccharide processing 
MOGS-CDG (CDG-IIb, OMIM 606065) symptoms include DD/ID, epilepsy, 
hypotonia, cerebral atrophy, small corpus callosum, optic nerve atrophy, hepato-
megaly, recurrent bone fractures, dysmorphic features, sensorineural hearing loss, 
and hypogammaglobulinemia (shortened immunoglobulin G half-life) (De 
Praeter et al 2000). Despite hypogammaglobulinemia, there seems to be increased 
resistance to certain viral infections. Serum Tf IEF shows normal pattern. 
Nevertheless, the N-glycan profile of immunoglobulin G was found to be 
abnormal in MALDI-TOF (matrix-assisted laser detection desorption ionization–
time-of-flight) MS (Sadat et al 2014; Peanne et al 2017).  
GANAB-CDG (OMIM 600666) and PRKCSH-CDG (OMIM 174050) cause 
autosomal dominant polycystic kidney disease and polycystic liver disease 
respectively. Serum Tf IEF shows normal pattern in both (Peanne et al 2017).  
MAN1B1-CDG (OMIM 614202) is characterized by DD/ID, hypotonia, 
dysmorphism, and truncal obesity (Rafiq et al 2011; Rymen et al 2013). 
MGAT2-CDG (CDG-IIa, OMIM 212066) symptoms include DD/ID, epilepsy, 
stereotypic movements, muscle atrophy, dysmorphic features, feeding 
problems, diarrhea, recurrent respiratory infections, and sensorineural hearing 
loss (Tan et al 1996; Ramaekers et al 1991). B4GALT1-CDG (CDG IId, OMIM 
607091) causes transient axial hypotonia, myopia, dysmorphic features, 
coagulation abnormalities, hepatopathy, and diarrhea. Normal psychomotor 
development is described as enzyme B4GALT1 has low expression in the brain, 
where other galactosyltransferases are more prevalent. Serum Tf IEF shows 
type 2 pattern in all three (Hansske et al 2002; Peters et al 2002; Guillard et al 
2011; Rymen et al 2013; Peanne et al 2017).  
SLC35A1-CDG (CDG-IIf, OMIM 603585), SLC35A3-CDG (OMIM 
615553) and SLC35C1-CDG (CDG-IIc, OMIM 266265; also known as 
leukocytes adhesion deficiency II) cause all DD/ID, epilepsy, hypotonia or 
ataxia. SLC35A1-CDG also shows proteinuria, bleeding; SLC35C1-CDG 
dwarfism, dysmorphic features, and recurrent infections with neutrophilia. 
Patients have a rare Bombay blood group (Lubke et al 1999; Martinez-Duncker 
et al 2005; Edvardson et al 2013). Serum Tf IEF shows type 2 pattern in 
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SLC35A1-CDG, but normal pattern in SLC35A3-CDG and SLC35C1-CDG. 
Oral Fuc has shown to reduce the infections in SLC35C1-CDG in some 
patients, but as some patients do not show benefit from Fuc treatment, more 
studies are needed in this matter (Marquardt et al 1999; Peanne et al 2017). 
SLC35A2-CDG (CDG-IIm, OMIM 300896) will be thoroughly discussed in 
Chapter 2.3. 
 
 
2.1.3.6. Defects in other proteins affecting N-glycosylation 
ATP6AP1-CDG (OMIM 300972) causes immunodeficiency (hypogamma-
globulinemia, recurrent bacterial infections), neonatal jaundice and hepa-
tosplenomegaly. It is X-linked disorder (Jansen et al 2016). ATP6V0A2-CDG 
(OMIM 219200, and 282250) symptoms are DD/ID, epilepsy, hypotonia, 
cobblestone-like brain malformation, myopia, skeletal anomalies and 
characteristic cutis laxa (Kornak et al 2008). CCDC115-CDG (CDG-IIo, OMIM 
616828) and TMEM199-CDG (CDG-IIp, OMIM 616829) cause liver disease, 
which can mimic Wilson disease due to low levels of serum ceruloplasmin. 
Contrary to CCDC115-CDG, patients with TMEM199-CDG show normal 
development (Jansen et al 2016a; Jansen et al 2016b). SLC39A8-CDG (CDG-
IIn, OMIM 616721) causes DD/ID, epilepsy, hypotonia, cerebellar atrophy, 
cranisynostosis, dwarfism, recurrent infections and hearing impairment as well 
as low manganese levels in blood. As an enzyme B4GALT1 is manganese-
dependent, defect in SLC39A8 leads to hypogalactosylation of glycans. 
Treatment with manganese and Gal is recommended (Park et al 2015). 
 The mutual symptoms of CDG caused by COG1, COG2, COG4, COG5, 
COG6, COG7 and COG8 defects include DD/ID, microcephaly, and hepatic 
dysfunction. In some, epilepsy, cerebral or cerebellar atrophy, recurrent in-
fections, failure to thrive and skeletal anomalies are seen (Peanne et al 2017). 
More patients are described with lobe B COG defects and hypothesis is that the 
clinical phenotype is less severe compared to lobe A defects (Haijes et al 2018). 
The difference in the phenotype severity between different COG-CDG subtypes 
might depend on how variants affect the whole COG complex integrity and 
function (Laufman et al 2013). 
Serum Tf IEF shows type 2 pattern in all (Park et al 2015; Jaeken and 
Peanne 2017; Peanne et al 2017).  
 
 
2.1.4. Other diagnostic methods of N-glycosylation defects 
2.1.4.1. Enzymatic testing and lipid-linked oligosaccharide analysis 
In case of type 1 Tf IEF profile and suspected MPI-CDG or PMM2-CDG, 
enzymatic assays from cultured fibroblasts or peripheral blood leukocytes are 
available to measure MPI or PMM activity. In case of PMM2-CDG, it is 
possible that PMM residual activity in fibroblasts is within normal limits, but 
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profoundly low in leukocytes. Therefore, enzymatic tests are neither confirma-
tive nor exclusive. Now, after detecting type 1 Tf IEF, first, the sequencing of 
PMM2 is suggested. A negative result should be followed by targeted CDG 
panel analysis or whole genome/exome sequencing (Grunewald et al 2001; 
Jaeken 2011; Cylwik et al 2013; Peanne et al 2017).  
 If the deficiency of MPI and PMM2 is excluded, LLO analysis in fibroblasts 
helps to evaluate the accumulation of glycan intermediates, which might give a 
hint to the possible molecular cause. LLO analysis was used to identify novel 
types of CDG-I caused by defects located in cytosol or ER. As N-glycosylation 
pathway in ER is highly conserved between humans and yeast, an accumulation 
of the substrate of affected reaction helped to identify the human ortholog to a 
culprit gene in yeast with similar finding. With LLO analysis, the patients’ cells 
are labeled with radioactive [2-(3H)]-Man, LLOs are extracted, and oligo-
saccharides are released from the lipid carrier, followed by high performance 
liquid chromatography analysis (Burda et al 1998; Peanne et al 2017). Neverthe-
less, LLO analysis might not be reliable in detecting the accumulation of short 
LLOs caused by defects in early LLO synthesis (Schwarz et al 2004). 
 
 
2.1.4.2. Glycoprofiling with mass spectrometry  
Different MS methods analyse the N-glycans of intact Tf or whole plasma 
glycoproteins. They give quantitative structural information about the glycans, 
and they can be used in diagnosing of CDG and monitoring the effect of 
therapy. MS can be used as the first step in CDG screening as MS analysis of 
intact Tf can quickly detect both, type 1 and type 2 CDG. In case of type 1 
defects, a loss of one or two complete N-glycans is detected. Otherwise, 
glycoprofiling is currently indicated for patients with type 2 pattern in 
screening, in order to detect the presence of specific truncated glycan structures, 
which might hint at the diagnosis. For instance, characteristic diagnostic 
profiles for intact Tf are seen with high-resolution MS in MGAT2-CDG (peak 
at two monoantennary complex N-glycans), B4GALT1-CDG (peak at two 
truncated biantennary glycans lacking Gal and Sia), SLC35A2-CDG (truncated 
glycans lacking one to four Gal-Sia disaccharides), MAN1B1-CDG (hybrid 
glycans), and PGM1-CDG (truncated glycans and loss of complete glycans). 
COG1-CDG and ATP6V0A2-CDG patients show increase of truncated 
structures with the reduction of Sia and Gal (van Scherpenzeel et al 2015). As 
previously mentioned, SLC35C1-CDG and SLC35A1-CDG can both show 
normal Tf IEF pattern and the first step in diagnostics should be MS. For 
SLC35C1-CDG, the whole plasma N-glycan profiling with MS shows decreased 
fucosylation. It is preferred over high-resolution MS of intact Tf, which shows 
non-specific decrease of fucosylation that is also evident in normal population. 
Inversely, in SLC35A1-CDG, the MS of whole plasma N-glycans is comparable 
with normal population, but with high-resolution MS of intact Tf, a loss of Sia 
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and increased peaks of di- and trisialylated Tf are seen (Guillard et al 2011; van 
Scherpenzeel et al 2015). 
In addition, high-resolution MS detects sensitively a loss of intact glycans in 
analyses where Tf IEF shows mild or near-normal type 1 profiles, and mild Tf 
IEF type 2 profile might turn out to be normal result or type 1 CDG with MS. The 
secondary causes of abnormal glycosylation with type 1 (galactosemia, fructo-
semia, alcohol abuse) or 2 (increased sialidase activity, liver disease) profile, and 
Tf polymorphisms can also be excluded with MS (van Scherpenzeel et al 2015).   
In conclusion, the detection of a specific diagnostic profile may lead to direct 
variant analysis and significantly shorten the time of reaching the diagnosis. MS 
of intact Tf is preferred as glycan levels are standardized to one protein instead of 
many. Still, MS is implemented in few laboratories at the moment (Guillard et al 
2011; van Scherpenzeel et al 2015; Van Scherpenzeel et al 2016; Peanne et al 
2017). 
 
2.1.4.3. Molecular diagnostics 
Molecular genetic analyses confirm the diagnosis of suspected CDG and are 
important in prenatal diagnosis for families with history of CDG. Since these 
analyses have become more available, their role has increased in the diagnostics 
of CDG. Different NGS techniques have helped to solve many screening-
positive (e.g. MAN1B1-CDG) as well as screening-negative (e.g. SLC35A2-
CDG) patients, and discover new disorders. Nowadays it is not unusual that 
NGS precedes biochemical studies and some patients have been diagnosed with 
CDG without previous suspicion of the disorder. 
 One way to approach molecular diagnosis is sequencing of single genes, 
especially if a certain type of CDG is suspected, based on clinical symptoms 
and biochemical studies. In case of CDG type I, first, sequencing of PMM2 is 
proposed (Peanne et al 2017). As the phenotype of CDG is often unspecific, 
variable, and overlapping, and may not indicate to a certain type of CDG, 
different gene panels (including CDG gene panel) are available as an alternative 
to single gene approach. They are more cost effective (Jones et al 2013).  
If gene panel results are negative, whole exome sequencing (WES) is another 
option for identifying the genetic cause of Mendelian disorders. Many variants of 
unknown significance, some of which are not disease causing, can be detected 
with gene panels or WES and must be evaluated carefully. In single cases it might 
be difficult to decide whether the findings are pathogenic or not, and diagnosis 
requires confirmation with functional assays, which may not be available for 
many gene defects yet (Ng and Freeze 2018). In addition, a previously not 
described variant in gene, which is assumed to cause a novel type of CDG, needs 
to be confirmed with functional studies. Complementation studies are often used. 
Alternatively, the availability of multiple unrelated individuals with similar 
phenotypes and variants in the same gene support the pathogenicity of the 
variants. Nevertheless, in some patients with suspicion of CDG due to clinical 
picture, positive Tf IEF or peculiar glycan profile in MS, the causative gene 
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remains unknown (Timal et al 2012; Jones et al 2013; Calvo et al 2018). In 
conclusion, the choice of first line molecular studies is determined primarily by 
the availability of specific NGS techniques in different institutions and countries. 
 
 
2.2. PMM2-CDG 
PMM2-CDG (former names carbohydrate-deficient glycoprotein syndrome, 
Jaeken syndrome, and CDG-Ia; OMIM 212065) is the most common CDG 
diagnosed worldwide. It was first reported in identical twin sisters by Jaeken 
and colleagues., followed by the discovery of the cause, decreased activity of 
the enzyme PMM2 fifteen years later (Jaeken et al 1980; Van Schaftingen and 
Jaeken 1995). According to the data from 12 European laboratories, PMM2-
CDG constituted 62% of all molecularly confirmed CDG (Peanne et al 2017). 
Interestingly, in Saudi Arabia, only two patients have been reported and other 
types of CDG seem to be more prevalent (Alsubhi et al 2017). The estimated 
frequency of PMM2-CDG might be as high as 1/20,000 (Schollen et al 2000) 
and in Sweden, the incidence has been reported to be 1/80,000 live births 
(Kristiansson et al 1998). 
PMM2-CDG is caused by variants in PMM2, which is located in chromo-
somal region 16p13 (Martinsson et al 1994; Matthijs et al 1997). Although 
inherited autosomal recessively, Schollen and colleagues have observed 
preferential transmission of PMM2 variants and increased recurrence risk in 
PMM2-CDG families (close to 1 in 3), which is possibly due to reproductive 
advantage (Schollen et al 2004). PMM2 encodes an enzyme PMM2, which 
converts Man-6-phosphate into Man-1-phosphate (Van Schaftingen and Jaeken 
1995). Subsequently, Man-1-phosphate is synthesized into GDP-Man, which is 
an essential substrate in N-glycan synthesis by being direct donor for LLO 
synthesis in cytoplasmic side of ER and precursor of Dol-P-Man. As Man is not 
only needed in N-glycosylation, PMM deficiency can affect multiple glycosy-
lation pathways. However, PMM2-CDG is classified as protein N-glycosylation 
disorder (Freeze et al 2015; Jaeken and Peanne 2017). 
As PMM2 influences the assembly part of LLO, Tf IEF shows type 1 profile. 
Still, false-negative results are described in adolescents and adults. In cultured 
fibroblasts and blood leukocytes, reduced activity of PMM2 is detected, 
although in fibroblasts, enzyme activity within normal limits is possible. There-
fore, sometimes the enzyme assay should be performed on freshly isolated 
leukocytes. PMM2 activity is also lower in PMM2 variant carriers without 
clinical symptoms (Matthijs et al 2000; Grunewald et al 2001). If PMM2-CDG 
is suspected based on the clinical symptoms and screening results, it would be 
reasonable to continue with PMM2 sequencing to confirm the diagnosis. 
Unfortunately, there is no specific treatment for the patients with PMM2-
CDG. Although effective in vitro, several interventions have not given expected 
effect in vivo. Alimentary Man does not improve the symptoms or protein 
hypoglycosylation, possibly due to Man-6-phosphate conversion to fructose-6-
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phosphate by MPI. Membrane permeable Man-1-phosphate proved to be toxic 
and unstable, enzyme replacement has not been tried, and increasing the Man-6-
phosphate flux into glycosylation pathway by combining the Man administra-
tion with the inhibition of the MPI activity is challenging (Freeze 2009). 
Pharmacological chaperones are potential novel therapeutic tool that might 
rescue protein folding for some PMM2 destabilizing variants where encoded 
protein has some residual activity (Yuste-Checa et al 2015). 
Nevertheless, symptomatic and interdisciplinary management is essential, 
and recently, international clinical guideline for the management of patients 
with PMM2-CDG was published (Altassan et al 2018). Patients may require 
tube and/or enhanced feeding, physical, speech and occupational therapy, medi-
cations like diazoxide, thyroxin, and antiepileptic drugs. Adequate hydration 
and avoidance of tissue damage are important for reducing the risk of throm-
botic complications. 
 
 
2.2.1. Phenotype of PMM2-CDG 
The clinical phenotype of PMM2-CDG and its severity are variable (Table 2). 
First described patients with PMM2-CDG showed marked DD, cerebral and 
cerebellar hypotrophy, delayed nerve conduction velocity, altered levels of 
different glycoproteins such as serum prolactin, growth hormone (GH), follicle-
stimulating hormone (FSH), and thyroxine-binding globulin (TBG) (Jaeken et 
al 1980). PMM2 is highly expressed in the liver but weakly in the brain. How-
ever, clinical picture always includes a moderate to severe neurological disease. 
With the classical phenotype, typical dysmorphic signs (inverted nipples, 
abnormal fat pads) and involvement of other organ systems are also additionally 
present (Matthijs et al 1997; Matthijs et al 1999). Three stages are differen-
tiated: the infantile multisystem stage, the late-infantile and childhood ataxia-
intellectual disability stage, and the adult stable disability stage. As the pheno-
type is more characteristic in children (especially with multiorgan involvement), 
PMM2-CDG is mainly diagnosed in early ages. 
 Prenatal period is usually uneventful, although non-immune fetal hydrops 
and hypertrophic cardiomyopathy might be present (Garcia Silva et al 1996; van 
de Kamp et al 2007). In infants, neurovisceral presentation is common, but 
isolated neurologic form is possible. In neonatal period, multisystem symptoms 
may include cardiac involvement (pericardial effusion, hypertrophic cardio-
myopathy), hepatopathy, enteropathy, coagulopathy, hyperinsulinemic hypo-
glycemia and feeding difficulties. In childhood, multiorgan involvement 
subsides and patients show hypotonia, ataxia and DD. They continue slowly to 
gain skills but in the majority of cases, ID ranges from moderate to severe.  
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Table 2. Clinical symptoms of PMM2-CDG (Altassan et al 2018). 
 
Dysmorphology Inverted nipples, fat pads, large protruding ears, prominent 
forehead, thin upper lip, prominent jaw, long and slender fingers 
and toes 
Neurology Axial hypotonia, hyporeflexia, delayed motor development, 
intellectual disability in variable degrees, non-progressive 
ataxia, dysarthria, seizures, stroke-like episodes, peripheral 
neuropathy, myopathy, microcephaly 
MRI findings Cerebellar atrophy, delayed myelination 
Opthalmology Strabismus, myopia, cataract, pigmentary retinopathy, 
nystagmus, transient cortical blindness 
Gastroenterology Failure to thrive, feeding difficulties, vomiting, protein-losing 
enteropathy, diarrhea, hepatomegaly and increased 
transaminases, cholestasis in infants 
Cardiology Pericardial effusion, hypertrophic cardiomyopathy, cardiac 
failure, conotruncal heart defects 
Nephrology Multicystic kidneys, enlarged kidneys, tubulopathy (proteinuria) 
Hematology Coagulopathy (bleeding, venous and arterial thrombosis), rarely 
thrombocytopenia and neutropenia 
Endocrinology Hyperinsulinemic hypoglycemia, hypothyroidism, short stature, 
hypergonadotropic hypogonadism, delayed or absent puberty 
Orthopaedics Kyphoscoliosis, osteopenia, joint contractures, thoracic 
deformities 
Biochemistry Elevated transaminases, FSH, luteinizing hormone (LH), 
prolactin, GH, thyroid-stimulating hormone (TSH, might be 
increased in newborn screening), insulin, ferritin 
Decreased factors IX and XI, ATIII, protein S, protein C, 
albumin, cholesterol, triglycerides, TBG, insulin-like growth 
factor 1 (IGF-1), insulin-like growth factor-binding protein 3, 
immunoglobulins, haptoglobulin, α-1-antitrypsin 
Other Recurrent infections, non-immune fetal hydrops 
 
 
Stroke-like episodes may be present up to half of the patients. These are often 
triggered by infection or head trauma, and present as an acute transient neuro-
logical episode with possible somnolence, stupor, seizures and/or hemiparesis. 
Full recovery may take hours to months. The brain MRI shows localized 
oedema not corresponding to any territory of arteries. In EEG, abnormal 
background and sometimes, focal seizures are seen. Vascular emergencies can 
also mimic stroke-like episodes (Schiff et al 2017, Altassan et al 2018). 
In adults, mild-to-severe ID, cerebellar ataxia, dysarthria, peripheral neuro-
pathy, kyphoscoliosis, osteopenia, thrombosis, retinitis pigmentosa, short 
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stature, cerebellar atrophy on MRI are described. They are often wheelchair 
dependent. Females have primary ovarian insufficiency. Subcutaneous fat pads 
are present in up to a third of adult patients (Krasnewich et al 2007; Monin et al 
2014; Wolthuis et al 2014). 
Despite the age, one of the most important symptoms in PMM2-CDG is 
cerebellar atrophy (both, vermis and hemispheres) in various degrees. It might 
not be present at birth but it usually develops later in almost all patients. The 
progression of atrophy has been reported in the first decade of life. Contrary to 
that, cerebellar symptoms do not show progression but they show stabilization 
or even mild improvement (de Diego et al 2017; Serrano et al 2017). 
According to recent studies in France and Spain, the mortality of PMM2-CDG 
ranges from 9 to 15%, and occurs mainly in early childhood among patients with 
multiorgan involvement (Perez-Cerda et al 2017; Schiff et al 2017). 
 
 
2.2.2. Variants and genotypes of PMM2-CDG 
PMM2 (MIM 601785) has eight exons and encodes a protein of 246 amino 
acids (Matthijs et al 1997). According to the data from 2018, PMM2 has at least 
129 pathogenic variants listed in the Human Gene Mutation Database 
(HGMD® Professional) from BIOBASE Corporation (Stenson et al 2009), and 
105 of them are missense variants. They affect the residual activity, affinity, 
structure and the stability of the PMM2 (Pirard et al 1999). Most of the variants 
are located in exons 5 and 8 (Vuillaumier-Barrot et al 2000).  
 Some variants are considered severe, as they lead to very low, almost absent 
residual activity of PMM2 (i.e. p.Arg123Gln, p.Arg141His, p.Phe157Ser, 
p.Thr237Arg), and some mild (p.Leu32Arg, p.Thr237Met, p.Cys241Ser), where 
residual activity of PMM2 ranges from 16 to 54% (Vega et al 2011). Variants in 
C-terminal part are associated, but not always, with a milder phenotype 
(Matthijs et al 2000).  
The majority of the patients are compound heterozygotes and have a combi-
nation of severe and mild variant (Vega et al 2011; Yuste-Checa et al 2015). A 
homozygous state of some variants is possible (Matthijs et al 2000; Neumann et 
al 2003; Najmabadi et al 2011; Perez et al 2011). The most common variant 
among Caucasian patients is p.Arg141His representing 21–50% of all variants in 
PMM2-CDG patients from different populations. Its homozygous state is 
considered lethal, as the PMM2 has no residual activity (Matthijs et al 1997; 
Matthijs et al 1998; Vuillaumier-Barrot et al 2000). Among PMM2-CDG 
patients, the second most common variants after p.Arg141His are p.Phe119Leu, 
p.Leu32Arg, p.Glu139Lys and p.Asp65Tyr in Scandinavia, Italy, France and 
Iberian Peninsula respectively (Matthijs et al 1997; Bjursell et al 1998; Le Bizec 
et al 2005; Perez et al 2011; Barone et al 2015; Schiff et al 2017). p.Val231Met is 
the third most common variant in Europe. Protein shows residual activity of 
38.5%, but is very unstable (Matthijs et al 1997; Pirard et al 1999).  
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2.2.3. Genotype-phenotype correlation of PMM2-CDG 
Observations about the genotype-phenotype correlations might help to consult 
PMM2-CDG patients and their parents about the possible course and prognosis 
of the disease. In case of PMM2-CDG, a clear correlation does not exist, 
especially between measured PMM2 residual activity and the severity of the 
disease. Patients with very low PMM2 activity can show a relatively mild 
phenotype and vice versa. Also, between the patients with the same genotype, 
differences in the disease severity can be seen, although interfamilial clinical 
homogeneity is generally observed (Grunewald et al 2001; Barone et al 2008; 
Schiff et al 2017). There is a possibility that the severity is also determined by 
other, environmental or genetic factors. For instance, concurrent polymorphism 
p.Phe304Ser in ALG6 causes more severe PMM2-CDG phenotype (Westphal et 
al 2002; Bortot et al 2013). In adult sisters with genotype p.Leu32Arg/ 
p.Thr237Met the phenotype difference was explained by ALG6 polymorphism 
present in one sibling (Bortot et al 2013). In adult males with genotype 
p.Arg141His/p.Val129Met the difference of severity correlated with different 
degree of Tf glycosylation which in turn correlated with PMM2 activity (Ba-
rone et al 2008). However, it remains unknown why the degree of hypo-
glycosylation differs between the patients with the same genotype. 
Milder phenotypes might be associated with variants that affect the folding 
and/or stability but not catalytic activity (Altassan et al 2018). Usually, in 
compound heterozygotes, severe variant is accompanied by milder one, which 
determines the phenotype. Genotypes p.Arg141His/p.Phe119Leu, p.Arg141His/ 
p.Val231Met and p.Val129Met/p.Arg141His usually cause a severe phenotype. 
The patients have severe DD, are bedridden or need supported walk, have visual 
defects, severe cerebellar atrophy, microcephaly and the presence of systemic 
involvement. A mild-moderate phenotype can be seen with p.Arg141His/ 
p.Cys241Ser, p. Leu32Arg/ p.Arg141His. The patients have mild-to moderate 
ID, cerebellar atrophy and they can walk independently. Also, it is not 
impossible that the patients are capable of living an independent life and acquire 
higher education. p.Arg141His/p.Thr237Met can cause a mild as well as severe 
phenotype (Grunewald et al 2001; Barone et al 2015).  
In Iberian Peninsula, lower prevalence of severe variants and therefore 
milder phenotypes are noted, whereas in Scandinavia, p.Arg141His/ 
p.Phe119Leu is common and patients show severe end of PMM2-CDG pheno-
type (Erlandson et al 2001; Perez et al 2011). 
 
 
2.3. SLC35A2-CDG 
SLC35A2-CDG (CDG-IIm, OMIM 300896) is a relatively new type of CDG. It 
is inherited by X-linked dominant manner and caused usually by de novo 
variants in SLC35A2 that locates on chromosome Xp11.23, and encodes the 
UDP-galactose/UDP-N-acetyl-galactosamine transporter (UGT) (Ng et al 
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2013). UGT is a transmembrane protein and delivers UDP-Gal and UDP-N-
acetyl-galactosamine in the Golgi. The N-terminal region of UGT plays the 
most important role in galactosylation (Sosicka et al 2014). Defects of UGT 
affect the galactosylation of N-glycosylated proteins. In addition, its defects 
also influence O-glycosylation of proteins, and glycosylation of lipids. 
In humans, UGT has two splice variants, UGT1 (transcript NM_ 
001042498.2) and UGT2 (transcript NM_005660.1), with slightly different C-
terminal amino acid sequence. Compared to UGT1, UGT2 has five different 
terminal amino acids and is three amino acids longer. UGT1 and UGT2 localize 
in the Golgi, and UGT2 also in ER. If UGT is defective, hypogalactosylation 
and subsequent hyposialylation occurs. Still, experimental studies in UGT-
deficient cell lines have shown an overexpression of UDP-N-acetylglucosamine 
transporter as well as its complexes with UGT that restore partial galacto-
sylation, and it is possible that UDP-N-acetylglucosamine transporter can 
partially replace UGT function (Olczak et al 2013). 
SLC35A2-CDG patients are mostly females and their phenotype includes 
rather non-specific severe symptoms as DD/ID, hypotonia, epilepsy and even 
epileptic encephalopathy, cerebral and cerebellar atrophy, dysmorphic features, 
and shortened extremities. Visceral symptoms are rare (Kodera et al 2013; Ng et 
al 2013).  SLC35A2 has been proposed as one of the candidate genes for early-
onset epileptic encephalopathy and cerebral visual impairment (Kodera et al 
2013; Euro et al 2014; Bosch et al 2016). As there are still relatively few 
patients who usually present with different variants, the genotype-phenotype 
correlations are not possible.  
The data from twelve European laboratories show that SLC35A2-CDG accounts 
7% of the type II CDG (Peanne et al 2017). The number of patients keeps rising and 
many of them are discovered by NGS, which sometimes precedes the investigations 
of serum glycoproteins. The diagnosis of SLC35A2-CDG can be challenging. Tf 
IEF and other screening methods show type 2 pattern, but not in all patients. In 
addition, pattern normalization in the early childhood is possible. The improvement 
of glycosylation does not correlate with the improvement of clinical symptoms (Ng 
et al 2013). With Tf MS, characteristic glycoprofile with truncated glycans and lack 
of Gal and Sia is seen (van Scherpenzeel et al 2015). Diagnosis is confirmed either 
by gene sequencing, gene panels or WES. According to HGMD® Professional, 
missense and frameshift variants from small deletions are described so far (Stenson 
et al 2009). In addition, somatic mosaicism in both, males and females, and skewed 
X-inactivation of mutant alleles in females have been reported. The positive 
selection for the wild type allele in hepatocytes might be the reason why some 
patients with SLC35A2-CDG show normal Tf glycosylation (Kodera et al 2013; 
Ng et al 2013). 
SLC35A2-CDG is one of the few CDG, where promising results are seen 
with oral Gal treatment as it improves the galactosylation, and therefore N-
glycosylation of glycoproteins by increasing UDP-Gal in cytosol. In addition to 
glycosylation, an improvement of the clinical condition and reduced seizure 
activity was reported in one patient (Dorre et al 2015). 
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2.4. Syntaxin 5 gene 
In Chapter 2.1.1.6., we shortly described the importance of COG complex in the 
retrograde trafficking of vesicles carrying resident Golgi proteins, and how the 
defects in COG subunits affect N-glycosylation. In addition to COG complex, 
other trafficking machineries such as Soluble N-ethylmaleimide-sensitive factor 
Attachment protein Receptors (SNAREs) are required for vesicular transport. 
They catalyze the vesicle docking and membrane fusion with the target 
membrane. SNAREs include many proteins that form different complexes with 
each other, and also with COG complex. Defects in COG complex destabilize 
SNAREs, cause impaired assembly of SNAREs complexes, lead to disturbed 
interactions between GOG and SNAREs complexes, and ultimately affect intra-
Golgi retrograde transport. Additionally, defects in SNAREs also cause disinte-
gration of the Golgi (Climer et al 2015). 
 Syntaxine 5 (STX5) is a member of SNAREs family. STX5 gene locates on 
chromosome 11q12.3. STX5 regulates the vesicle-mediated protein transport, 
docking and fusion in every cell. In vitro, it has been shown to regulate ER-to-
Golgi transport in yeast (Ravichandran and Roche 1997). This transmembrane 
protein localizes in the cis-Golgi region and forms together with other SNAREs 
complexes with subunits COG4, COG6 and COG8 (Laufman et al 2013). Pre-
sently, no pathogenic variants in STX5 gene have been described in humans. 
 
 
 
2.5. Summary of the literature review 
CDG has become a rapidly expanding diverse group of metabolic diseases. 
Many patients all over the world are diagnosed with different types of CDG, 
and the number keeps rising. In spite of that CDG seemed to be under-
diagnosed in Estonia. It has been partly due to its unfamiliar, variable, and non-
specific symptoms, and also because of the limited availability of diagnostic 
tests. Nevertheless, serum Tf IEF has remained the main method of choice of 
CDG screening since its introduction in the early eighties. To determine the 
occurrence of CDG in patients in Estonia, first, our aim was to implement 
serum Tf IEF in routine clinical practice. To our knowledge, similar CDG pilot 
screening has not been previously reported in other populations. In addition, the 
results of CDG screening have led to many discoveries, which have helped to 
add new clinical and epidemiological data about different known types of CDG, 
but also to expand the group of CDG by the discovery of the new type of CDG.  
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3. AIMS OF THE PRESENT STUDY 
The aims of the present study were: 
 
1.  To establish and evaluate the effectiveness of Tf IEF in screening of CDG in 
Estonia; 
2.  To evaluate the genotype and phenotype of Estonian PMM2-CDG patients; 
3.  To study the expected frequency of PMM2-CDG based on Estonian popula-
tion data, and the prevalence of PMM2-CDG based on diagnosed patients in 
Estonia; 
4.  To characterize and compare the clinical phenotype and the genotype of 
Estonian SLC35A2-CDG patient with a cohort of international patients with 
SLC35A2-CDG; 
5.  To present a patient with a novel type II CDG likely caused by homozygous 
variant in STX5 gene. 
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4. MATERIAL AND METHODS 
4.1. Study subjects 
4.1.1. Cohort screened with transferrin isoelectric focusing 
The pilot screening period lasted from June 1, 2012 to June 30, 2015. To im-
prove the coverage of the patients with possible CDG, Tf IEF was performed to 
all patients whose serum samples were sent to Department of Clinical Genetics 
in Tartu University Hospital for any metabolic analyses. Therefore, the whole 
cohort was formed from two groups of patients – the ones whom the clinicians 
requested intentionally Tf IEF alone or among other metabolic analyses, and the 
patients whose samples were analyzed primary for other metabolic diseases. 
The samples were sent from Tartu University Hospital (Department of Clinical 
Genetics and its subunits from Tartu and Tallinn, Children’s Clinic, Psychiatry 
Clinic, Internal Medicine Clinic, Surgery Clinic, and Neurology Clinic), Tallinn 
Children’s Hospital, West Tallinn Central Hospital (Multiple Sclerosis Centre), 
East Tallinn Central Hospital, and the North Estonia Medical Centre. 
In a 37-month screening period, Tf IEF was performed to 1230 patients. In 
addition, in 52 patients, the screening was repeated once or twice in different 
time periods based on the results of the first screening or by the request of the 
treating clinician. The age distribution of screened patients (N=1229, the age of 
one patient remained unknown) is shown in Figure 6. 
 
 
 
 
 
 
 
 
Figure 6. The age distribution of screened patients from June 1, 2012 – June 30, 2015. 
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4.1.2. Subjects in PMM2-CDG prevalence study 
4.1.2.1. Population cohort 
At the time of the study period, the population-based biobank of the Estonian 
Genome Center at the University of Tartu (EGCUT) represented 5% of 
Estonian adults, and it has been a unique database for research (Leitsalu et al 
2015). In 2016, the query for the whole genome sequencing (WGS) data of 
2,244 individuals from EGCUT was submitted to assess the presence and 
frequency of disease-causing variants in PMM2 among biobank participants. 
WGS samples were sequenced at the Broad Institute (Cambridge, Massachu-
setts, USA). Libraries were sequenced on the Illumina HiSeq X Ten (Illumina, 
San Diego, California, USA). 
 
4.1.2.2. Patients cohort 
Altogether, four Estonian patients with PMM2-CDG from two families were 
alive and were included in prevalence calculations. All patients were diagnosed 
during the pilot screening period and were also included in the screening cohort 
(Chapter 4.1.1.). They all had type 1 pattern in Tf IEF and PMM2-CDG was 
molecularly confirmed. 
 
 
4.1.3. Subjects in SLC35A2-CDG study 
4.1.3.1. Estonian patient with SLC35A2-CDG 
A male patient with type 2 Tf IEF was molecularly confirmed with SLC35A2-
CDG. His clinical, biochemical, neuroradiological (including the data of the 
brain magnetic resonance imaging, MRI) and molecular data were collected and 
compared with international patients’ cohort data. 
 
4.1.3.2. International patients with SLC35A2-CDG 
The clinical, biochemical, neuroradiological and molecular data of 14 patients 
(11 females and 3 males) from nine different countries and thirteen clinical 
centers were collected. Three patients in the cohort were previously shortly 
described in other papers (Bosch et al 2016; Lopes et al 2016; Demos et al 
2017). In eight patients, the brain MRI data were available for re-evaluation of 
neuroradiological features. 
 
4.1.4. Subjects with new type of CDG 
A male patient (proband 1) with multisystem presentation was screened for 
suspected CDG in the neonatal period, and showed type 2 Tf IEF. His clinical, 
biochemical, radiological and molecular data were collected and compared with 
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the clinical, radiological and molecular data of the fetus from his mother’s 
previous aborted pregnancy (proband 2). 
 
 
4.2. Methods 
4.2.1. Screening of N-glycosylation disorders 
4.2.1.1. Serum transferrin isoelectric focusing 
The protocol of Tf IEF from Radboud University Medical Center, Nijmegen 
was used as the primary source for this method (unpublished). 
Patient’s serum was centrifuged at 11 000 RPM for 10 minutes. Ten μl of 
serum was mixed with 10 μl solution of Fe(III)citrate/0.5M sodium bicarbonate. 
The sample was incubated for 30 minutes at room temperature and then diluted 
with 100 μl ultrapure water (Milli-Q).  
To exclude Tf polymorphism and remove Sia, 3 μl of serum was mixed with 
3 μl solution of Fe(III)citrate/0.5M sodium bicarbonate. The sample was 
incubated for 30 minutes at room temperature. Then, 1.5 μl of neuraminidase 
10U/ml from Clostridium perfringens (Roche) was added and the sample was 
incubated overnight at room temperature. The next day, the sample was diluted 
with 90 μl ultrapure water.  
Gel (PhastGel Dry IEF, GE Healthcare) was hydrated in 125 μl ServalytTM 
5–7 carrier ampholyte (SERVA) solution with 4875 μl ultrapure water, and 
incubated for at least 90 minutes at room temperature. 
For IEF, GE Healthcare Phast System was used, which allows to run IEF on 
two gels at a time. Hydrated gel was layed on a cooling plate (15 C°). The 
sample amount of 1.3 μl was pippeted on the paraffin film, and then applied on 
the gel using a special sample comb. On both gels, up to eight samples could be 
applied, with one used as positive control sample. Gel was run with the 
following program: 
 
Step 1 2000 V 2.0 mA 3.5 W 15 C° 485 Vh Prefocusing 
Step 2   200 V 2.0 mA 3.5 W 15 C°   15 Vh The application of samples 
Step 3 2000 V 5.0 mA 3.5 W 15 C° 130 Vh Separation 
Step 4     50 V 0.5 mA 0.5 W 15 C°   50 Vh  
 
After IEF, gel was immunoprecipitated for 30 minutes with 60 μl of polyclonal 
rabbit anti-human transferrin (DAKO), and subsequently repeatedly washed in 
NaCl 0.9% solution overnight. 
The next day gel was fixated in 20% trichloroacetic acid solution for 10 
minutes. Then, gel was coloured with Coomassie blue solution (GE Healthcare 
PhastGel Blue R-350) for 30 minutes and subsequently washed repeatedly with 
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the solution of 30% ethanol/10% trichloroacetic acid. Finally, the gel was dried 
in the room air.  
Tf IEF pattern and the intensity of sialotransferrin bands were evaluated only 
qualitatively.  
 
4.2.1.2. Subjects with positive screening 
In patients with type 1 Tf IEF pattern NGS of a large gene panel (TruSight One, 
Illumina Inc., San Diego, CA) with confirmation of PMM2 variants with Sanger 
sequencing were performed (Tartu University Hospital). The PMM2 activity in 
skin fibroblasts was studied only in one patient (Radboud University Medical 
Center, Nijmegen). 
To the patients with type 2 Tf IEF pattern, quantitative Tf IEF, ApoC-III 
IEF, serum Tf quadrupole time-of-flight MS, Illumina chromosomal microarray 
analysis, NGS and/or WES were done (Radboud University Medical Center and 
Tartu University Hospital). 
In addition, the samples of two subjects from the screening cohort with 
indicative CDG pattern in Tf IEF were sent to Radboud University Medical 
Center either for quantitative Tf IEF and/or ApoC-III IEF. 
The clinical data were collected from the electronic health record databases. 
 
 4.2.2. Statistical analysis of PMM2-CDG prevalence study 
A paper by Schollen et al. (Schollen et al 2000) was taken as a basis in 
calculating the expected PMM2-CDG frequency in Estonia. We used the 
assumption that only p.R141H homozygosity is embryonically lethal (Matthijs 
et al 1998). We modified Hardy-Weinberg equilibrium as follows: the expected 
disease frequency in the Estonian population equals r2+2qr where q is the allele 
frequency of p.R141H and r the combined allele frequency for other identified 
variants in the cohort. All statistical analyses were conducted in R version 3.2.3 
(R Core Team 2016). 
 
4.2.3. Investigations in the SLC35A2-CDG study 
4.2.3.1. Estonian patient with SLC35A2-CDG 
Tf IEF was performed according to the protocol. The quantitative Tf IEF, 
ApoC-III IEF, serum Tf quadrupole time-of-flight MS were done in Radboud 
University Medical Center. For molecular diagnostics HumanCytoSNP-12 
BeadChips (Illumina Inc., San Diego, California, USA), NGS of a large gene 
panel (TruSight One, Illumina Inc., San Diego, California, USA) and sub-
sequent WES were performed.  
A questionnaire was created for the clinical and biochemical data to 
standardize information collection from the international collaborators. The 
clinical and the brain MRI data were collected from the electronic health record 
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database. The 1.5 or 3T brain MRI data were re-evaluated by two neuro-
radiologists. Age specific MRI reference data for the biometry of the corpus 
callosum in children was used for the assessment of corpus callosum length 
(Garel et al 2011). Short stature was defined as height or length less than 5 
percentiles. Z-scores were calculated by using the CDC Height for Age 
Percentiles for Girls or Boys (2– 20 years) and CDC/NCHS Infant Length for 
Age Percentiles (< 36 months) (https://reference.medscape.com/guide/medical-
calculators). 
 
4.2.3.2. International patients with SLC35A2-CDG 
Molecular genetic studies and Tf isoform analyses were performed in different 
institutions. All variants in SLC35A2 were discovered using WES. Conforma-
tional studies and familial segregation analysis were commonly performed 
using Sanger sequencing. 
A questionnaire about the clinical and biochemical data was sent to 
corresponding clinicians. In eight patients, the brain MRI was available for re-
evaluation by two neuroradiologists. Age specific MRI reference data for the 
biometry of the corpus callosum in children was used for the assessment of 
corpus callosum length (Garel et al 2011). Short stature was defined as height or 
length less than 5 percentiles. Z-scores were calculated by using the CDC 
Height for Age Percentiles for Girls or Boys (2–20 years) and CDC/NCHS 
Infant Length for Age Percentiles (< 36 months) (https://reference.medscape. 
com/guide/medical-calculators). 
 
4.2.4. Investigations of the subjects with new type of CDG 
Tf IEF was done to proband 1 according to the protocol. In addition, quan-
titative Tf IEF, ApoC-III IEF, serum Tf quadrupole time-of-flight MS were 
done in Radboud University Medical Center. 
DNA of proband 1 was extracted either from peripheral blood according to 
the standard salting out protocol, and in proband 2, from amnionic fluid cell 
culture. Screening for chromosomal abnormalities was performed using 
HumanCytoSNP-12 BeadChips (Illumina Inc., San Diego, California, USA). 
Genotypes were called by GenomeStudio v2011.1 software and the data were 
analyzed by using GenomeStudio Genome Viewer tool (Illumina Inc.). The 
minimum threshold for the regions of long contiguous stretches of homo-
zygosity (LCSH) was set at 5 Mb.  
WES was done in Radboud University Medical Center. The probable 
candidate gene for the phenotype of probands is STX5, which is located in one 
LCSH and is not previously associated to CDG. The functional studies are in 
work in order to find out how this gene affects glycosylation pathways (the data 
are inconclusive).  
The clinical data of the probands was collected from the electronic health 
record databases. 
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4.2.5. Ethical approval 
This study was approved by the Research Ethics Committee of the University of 
Tartu (181/T-16, 20.04.2009 and 235/M-13, 17.03.2014). Informed consent was 
obtained from the parents or legal guardians of the patients to whom additional 
studies were indicated due to positive screening of N-glycosylation.  
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5. RESULTS AND DISCUSSION 
5.1. Screening of N-glycosylation disorders in Estonia 
Altogether, 1230 patients were screened for N-gycosylation disorders in the 
study period. In addition, we repeated Tf IEF in 52 new samples taken from the 
patients whose first Tf IEF pattern was possibly indicative to N-glycosylation 
disorders, or when clinicians decided to repeat the analysis.  
The analyses were mainly performed to children aged 1–6 years (44%). 
Infants constituted 19%, children aged 7–17 years 21%, and adults 16% of all 
the screened patients. As expected, Tf IEF was mainly investigated in children, 
and most of the time, the screening was ordered among many other metabolic 
analyses. Out of six patients with a positive screening result and confirmed 
CDG diagnosis, CDG was suspected and studied in five, and only one patient 
reached the diagnosis due to the expanded screening strategy, as Tf IEF was not 
ordered in the first choice. Department of Clinical Genetics in Tartu University 
Hospital is the only center in Estonia that consults the patients suffering from 
inborn errors of metabolism, and offers screening of N-glycosylation disorders. 
Therefore, it is highly likely that we are aware of all molecularly confirmed 
CDG patients in Estonia. As CDG is relatively new but also a rare group of 
metabolic diseases, the overall awareness of the disease among clinicians has 
been consequently low. All our positive screening results were seen among 
children in different ages. Adult age group was modestly represented and often 
the samples were sent for other metabolic analyses. One cause for more exten-
sive use of different metabolic studies among children is the involvement of 
clinical geneticists in the consulting process. Nevertheless, the presence of 
undiagnosed patients, especially among adults, is possible. Some of the patients 
might be deceased, have milder disease course or have undergone diagnostic 
work-up many years ago when the awareness of CDG and the availability of 
different diagnostic procedures (Tf IEF, NGS panels, WES) were insufficient. 
During the study period, six patients with three different N-glycosylation 
disorders were detected. There seems to be no reports of such expanded CDG 
pilot screenings in other populations, but reports about the experiences with N-
glycosylation disorders in single or multiple centers have been published in 
different countries. In a single institution in Dubai, ten patients with seven 
different type of CDG were reported, and similarly in Canada, 15 patients with 
seven different CDG were diagnosed (Al Teneiji et al 2017; Bastaki et al 2018). 
Recently, the results of a 10-year period of CDG screening from Argentina were 
published, where seven patients out of 554 studied patients showed abnormal Tf 
IEF profile and had molecularly confirmed CDG diagnosis (Asteggiano et al 
2018). Multi-center experiences reports come from Saudi Arabia and Spain. In 
Saudi Arabia, 27 patients with six types of CDG were reported (Alsubhi et al 
2017). During a 20-year period, 97 patients with 18 different CDG caused by N- 
or combined N- and O-glycosylation disorders were diagnosed in different 
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hospitals in Spain, where all the patients with multisystem disease of unknown 
etiology were studied. Interestingly, different screening methods (including Tf 
IEF) showed positive results in all their molecularly confirmed CDG patients 
(Perez-Cerda et al 2017). 
Tf IEF can be positive in up to 48 different CDG (Table 1) and it covers 
most of the N-glycosylation disorders and disorders of combined or other 
glycosylation pathways affecting N-glycosylation pathway (Jaeken and Peanne 
2017). Nevertheless, there are some limitations in this study. First, the evalua-
tion of screening was subjective and we could not quantify the intensity of 
different sialotransferrin bands. This could lead to false positive or false 
negative interpretations. If the pattern seemed to refer to CDG, the clinicians 
were asked to repeat the analysis after one or two months. The analyses of the 
newborns were always asked to be repeated as in newborns, the results can be 
either false negative or refer to mild type 2 profile. It is possible that in some 
cases, analyses were not repeated. There is also a possibility that the same 
patient was diagnosed with another disease, which eliminated the need for 
repeated CDG screening. Altogether, the serum samples of two patients from 
the whole cohort were sent to Nijmegen University Hospital for quantification 
and additional glycosylation studies if indicated (Chapter 5.1.2.).  
Opposite, some patients might show very mild positive pattern that is 
qualitatively very difficult to evaluate as disease referring and leads to false 
negative interpretation. Age-dependent false negative results are also possible 
and cannot be excluded. At the same time, two CDG-patients with mild pheno-
type showed strong type 1 pattern despite their older age. 
Second, as seen in some types of CDG (e.g. ALG13-CDG, SLC35A2-CDG) 
both normal and abnormal Tf IEF pattern is described, which could lead to 
premature exclusion of CDG. In addition, some N-glycosylation defects like 
MOGS-CDG or SLC35A3-CDG always show normal screening results. It is 
important for clinicians to think about these aspects and even if, regardless the 
negative screening, the suspicion of CDG remains, another diagnostic analyses 
like whole plasma glycoprotein or intact Tf MS, gene sequencing, gene panels 
or WES should follow Tf IEF. 
Third, with extended use of NGS, it is important to carefully interpretate its 
results. Not all identified variants are deleterious and cause CDG (Chapter 
5.1.4.).  
Next, more detailed information of positive screening results and false 
positive screening results are given. In addition, two patients with variants in 
glycosylation-related genes but negative screening are presented. 
 
 
5.1.1. Positive screening results 
Clearly abnormal Tf profile was found in six patients. Positive type 1 Tf IEF 
pattern was present in four patients from two families. All the patients had 
molecular confirmation for the most common PMM2-CDG. In family 1, Tf IEF 
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was first ordered to a 10-month old girl, and showed classical increase of di- 
and asialotransferrin. As her older siblings had also shown DD, Tf IEF was 
performed with their serum samples and the results showed similar pattern to 
their sister.  
In family 2, Tf IEF was ordered to a 3-month old girl with neurovisceral 
symptoms. The clinical phenotype of all PMM2-CDG patients is thoroughly 
described in Chapter 5.2. 
Positive type 2 Tf IEF pattern indicating either N-glycosylation or multiple 
pathway disorder was seen in two patients. The patient 1 was almost 2 years old 
male, when in search of a possible cause of mitochondrial Leigh syndrome, 
other metabolic analyses were ordered and Tf IEF was first done as expanded 
screening. Positive screening led to additional glycosylation studies and finally, 
SLC35A2-CDG was molecularly confirmed by WES. At the age of 4-years the 
patient still showed type 2 Tf IEF pattern. In SLC35A2-CDG, the isoforms of 
Tf have been reported to normalize already in the early childhood, and this 
might cause a delay in diagnosis (Ng et al 2013). 
The second male patient with type 2 Tf IEF pattern died at the age of 25 
days. CDG screening was ordered from the serum taken on the 5th day of life. 
The patient had a new, type 2 CDG, which affects multiple pathways of glyco-
sylation. 
The clinical phenotype of these two patients is thoroughly described in 
Chapters 5.4. and 5.5. 
 
5.1.2. False positive screening results 
Two samples were sent to Radboud University Medical Center for quantitative 
measurements of sialotransferrin and other glycosylation studies when 
indicated. In a 16-year old female patient with severe DD/ID, microcephaly, 
brain atrophy and epilepsy, an increased trisialotransferrin was present, which 
indicated possible type 2 CDG. For instance, the patients with MAN1B1-CDG 
show an increase of trisialotransferrin (Rymen et al 2013). Quantification of Tf 
isoforms showed isolated increase of trisialotransferrin (16.9%, normal limits 
4.9–10.6%). ApoC-III IEF was also abnormal (increased ApoC-III2 and 
decreased ApoC-III1) indicating an increased level of Sia on mucin type O-
glycans. The MS was not performed due to the limited amount of sample. As 
the WES did not reveal CDG-associated changes, we can probably exclude 
CDG. The patient is deceased, and further analyses are not possible. 
Another patient with false-positive screening result was a 5-month old boy 
with DD, hypotonia and normal brain MRI. Repeated Tf IEF profile was 
suggestive to mild type 2 pattern. Quantification revealed that the sialotrans-
ferrins were within normal limits. 
 
  
 47
5.1.3. Patient with a variant in ALG13 and  
negative screening result 
A 4-year old patient was diagnosed with Lennox-Gastaut syndrome at the age 
of 3 years. In addition, he had slightly delayed speech development, but no 
visceral symptoms. Brain MRI showed focal cortical dysplasia in mesial 
temporo-occipital area. A targeted NGS panel of epilepsy-associated genes 
revealed missense variant c.1641A>T, p.Gln547His in ALG13 (Moller et al 
2016). Tf IEF was done after molecular analysis and showed normal result.  
ALG13 encodes ALG13 protein, which is a subunit of GlcNAc-transferase. 
ALG13 forms complex with ALG14 and adds the second GlcNAc to GlcNAc-
PP-Dol in the early steps of N-glycan synthesis. Variants in ALG13 are 
considered to be associated with epileptic encephalopathy, seen both in males 
and females (Epi et al 2013). Variants are inherited in a X-linked manner. In 
female patients, random X-inactivation pattern is described (Hamici et al 2017). 
The most frequently reported de novo variant p.Asn107Ser is confirmed mainly 
in female patients with severe phenotype including epileptic encephalopathy. A 
hypothesis was, that this variant is lethal in males. In 2017, first male patient 
with p.Asn107Ser was reported (Galama et al 2018).  
As ALG13 is important enzyme in N-glycosylation, variants in ALG13 could 
presumably cause ALG13-CDG. The first patient with ALG13-CDG was 
described by Timal and colleagues in 2012 (Timal et al 2012). The deceased 1-
year old male patient had visceral symptoms and refractory epilepsy. Abnormal 
type 1 Tf IEF was seen, and compared to the control sample, reduced GlcNAc-
transferase activity was measured in fibroblasts. Thereafter, patients with 
ALG13 variants but normal screening have been described. In few reported 
females, glycosylation studies were limited to CDG screening with negative 
results, whereas in some reported males other glycosylation studies were per-
formed in addition.  
Recently, a boy with infantile spasms and the commonest ALG13 variant had 
normal Tf IEF but MS of Tf revealed minor glycosylation abnormalities 
(Galama et al 2018). Another male patient with slightly delayed motor but 
normal cognitive development and seizures was reported. He showed normal Tf 
IEF but cellular glycosylation assay confirmed abnormal glycosylation with 
reduced expression of ICAM-1. The mother of the patient carried the variant but 
was asymptomatic (Gadomski et al 2017). The mother and grandmother of 
Estonian patient are also unaffected carriers of p.Gln547His.  
Unfortunately, due to limited accessibility, similar glycosylation assays have 
not been done to Estonian patient (e.g. enzyme assay is not available at the 
moment) and it remains unknown whether despite the negative screening the 
glycosylation is affected. The c.1641A>T variant detected in the patient is 
absent from the Genome Aggregation Database (gnomAD) and in-silico 
pathogenicity prediction algorithms show inconsistent results, thus according to 
American College of Medical Genetics and Genomics (ACMG) variant classi-
fication criteria (Richards et al 2015) this variant is of uncertain significance. 
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However, pathogenicity could not be ruled out at this moment. Therefore, to 
further investigate the pathogenicity of this variant, functional studies are 
needed in order to diagnose ALG13-CDG. In addition, as only the epilepsy-
associated genes have been studied, one cannot exclude that there is another, 
unstudied cause for his symptoms. 
 
 
5.1.4. Patient with homozygous variant in ALG6 
A 13-year old male patient was consulted due to asymmetric progressive 
spasticity in legs. Perinatal anamnesis was uneventful. In late infancy, delayed 
gross motor development was noticed. The patient had a speech and language 
delay. In spite of that he has been able to attend in regular school program. His 
growth was normal. He showed brisk reflexes, spasticity and ankle clonus. In 
brain MRI a large arachnoidal cyst behind the medulla and narrow isthmus of 
corpus callosum was seen. Tf IEF was normal. WES revealed homozygous mis-
sense variant c.391T>C, p.Tyr131His in exon 6 of ALG6, which was confirmed 
with Sanger sequencing. His parents were heterozygous for p.Tyr131His. In 
addition, reanalysis of WES data detected de novo missense variant c.20G>A, 
p.Gly7Glu in CBX8. Encoded protein CBX8 plays role in the repair of DNA 
lesions (Oza et al 2016). The functional studies are presently at work for 
proving the pathogenicity of CBX8 variant. 
An enzyme ALG6 adds the first Glu to LLO. The prevalence of ALG6-CDG 
is 8% of all CDG in the Europe cohort (Peanne et al 2017). It causes DD/ID, 
hypotonia, ataxia, proximal muscle weakness, epilepsy and failure to thrive. 
Cerebellar hypoplasia has not been observed. Tf IEF shows type 1 pattern and 
LLO analysis accumulation of Man9GlcNAc2 intermediate. The most common 
variant is p.Ala333Val (Grunewald et al 2000; Morava et al 2016).  
In North American population, variant p.Tyr131His is also frequent and 
estimated frequency of its homozygotes is 1/2200, whereas in Croatia, 1/1000 
(Westphal et al 2003; Goreta et al 2012). In EGCUT cohort, the homozygosity 
of p.Tyr131His is present in two subjects (2/2244). At the same time, 
p.Tyr131His homozygosity was reported in an adult female with diagnosis of 
ALG6-CDG. She showed early hypotonia, enteropathy, strabismus, cortical 
blindness, partial agenesis of corpus callosum, myoclonus and cerebellar syn-
drome. Tf IEF was normal. Enzymatic analysis in skin fibroblasts showed 
normal LLO size, but the complementation analysis of ALG6-deficient yeast 
indicated that variant p.Tyr131His was severe and did not rescue defective 
glycosylation (Westphal et al 2003; Miller et al 2011). Although the variant is 
located in conserved sequence, it remains controversial whether p.Tyr131His is 
just a polymorphism or its homozygosity can cause ALG6-CDG. Contrary to 
the patient described here, a reported female patient had symptoms consistent 
with ALG6-CDG. In a recent review of 41 patients with ALG6-CDG, 
p.Tyr131His was considered as a polymorphism that was present in three 
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patients in addition to two other ALG6 variants, and it did not seem to affect the 
severity of their phenotype (Morava et al 2016).  
We conclude that the patient does not have ALG6-CDG, and it is more 
likely that the disease is caused by other factors, for example, the studies 
clarifying the role of CBX8 gene variant are ongoing. 
 
 
5.2. Patients with PMM2-CDG  (Paper I) 
Type 1 pattern in Tf IEF led to PMM2-CDG diagnosis in two infants and two 
school-aged children from two families. In family 1, two older patients with 
mild clinical presentation got their diagnosis in adolescence after the diagnosis 
of their youngest sibling (Vals et al 2017). The older sibs had been consulted 
and investigated by the clinical geneticist in their early childhood. At that time, 
however, Tf IEF was not widely accessible in Estonia and CDG was not 
studied. In family 2, the child presented with classical phenotype of PMM2-
CDG. 
 
5.2.1. Phenotype 
In family 1 and 2, the parents of the sibling(s) are non-consanguineous and all 
children were born at term after an uncomplicated pregnancy and delivery. In 
family 1, both parents are Estonians and in family 2, one parent is French and 
the other is Estonian. 
 In family 1, PMM2-CDG was first diagnosed in the youngest sibling at the 
age of 10 months. She presented with delayed motor skills, muscular hypotonia, 
truncal ataxia, and strabismus. At the time of diagnosis she was not crawling 
and sat insecurely. Her cognitive development and growth parameters were 
appropriate for her age. She started to walk independently at the age of 21 
months and she has had a delayed speech development. The brain MRI has not 
been done. 
Her siblings also had problems with gross motor development and ataxia in 
infancy and early childhood. Older brother (16 years old) started to walk at the 
age of 19 months and his speech development was delayed. Older sister (8 years 
old) started to walk at 21 months of age but had normal speech development. 
The brain MRI of both probands showed cerebellar atrophy (Figure 7). 
Interestingly, progression of atrophy was not evident in the brother although the 
MRIs were done at the ages of nine and seventeen. According to the Wechsler 
Intelligence Scale for Children (WISC) done at the age of diagnosis, the full 
scale IQ scores were 72 (borderline) and 81 (low average) for brother and older 
sister respectively, which are normal. Older sister studies in basic school and 
brother has graduated the high school and continues his education at the 
vocational education center.   
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All sibs have needed orthodontic treatment because of occlusion abnormalities. 
All have shown some coagulation abnormalities (including low ATIII), and 
females increased FSH and LH. 
All children showed a clear type 1 pattern on serum Tf IEF. In the male 
patient, enzymatic analysis showed a residual activity of PMM2 in skin 
fibroblasts 1.6 mU/mg (normal limits 4.7–9.2, i.e. 34% of the normal lower limit). 
In family 2, the female patient was hospitalized at the age of 3 months due to 
failure to thrive, and vomiting. She showed abnormal fat pads and inverted 
nipples, strabismus, DD, hypotonia, pericardial effusion and myocardial 
hypertrophy, relatively high transaminases, hypoalbuminemia, and low levels of 
ATIII. In addition, she is diagnosed with bilateral sensorineural deafness and 
hypothyreosis. Central blindness is suspected. The brain MRI showed hypo-
plasia of the vermis, cerebellar atrophy and hypomyelination. Tf IEF showed 
type 1 profile. Enzymatic analyses were not done. 
The development has been severely delayed and she is fed through gastro-
stomy. At the age of one year, the symptoms worsened due to adenoviral in-
fection, dehydration and possible sepsis. During decompensation, pericardial 
effusion worsened and was accompanied by ascites. Coagulopathy was evident. 
Biochemical analyses showed even more decreased albumin and ATIII, thrombo-
cytopenia and increased transaminases. This illustrates that in patients with 
PMM2-CDG, stressful conditions, such as infections, quickly destabilize the 
multisystem symptoms of the disease, which can be possibly life threatening. 
 
5.2.2. Genotype 
In family 1, NGS of a large gene panel (TruSight One, Illumina Inc., San Diego, 
California, USA) in the youngest sibling revealed compound heterozygosity for 
two previously reported variants in exon 8: c.691G>A (p.Val231Met) and 
c.715A>T (p.Arg239Trp). Sanger sequencing confirmed PMM2 variants in all 
sibs and their parents. 
In family 2, PMM2 sequencing confirmed compound heterozygosity for 
c.368G>A (p.Arg123Gln) in exon 5 and c.619G>A (p.Val231Met) in exon 8. 
 
 
5.2.3. Genotype-phenotype correlation 
As seen from these two families, the severity of PMM2-CDG can be variable. If 
the patient shows characteristic phenotype, the diagnosis is often made in 
infancy. In addition to severe phenotype, more patients with mild or moderate 
phenotypes are reported, which makes the diagnosis challenging. These patients 
have presented either with failure to thrive and increased level of transaminases, 
or with the symptoms of the nervous system like gross motor DD, ataxia, 
hypotonia and/or cerebellar hypoplasia with preserved ability to ambulate 
independently and participate in regular school programs. Hence, it is important 
to screen CDG in patients even with subtle neurological symptoms and normal 
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cognitive development. According to recent PMM2-CDG guidelines, only 12% 
of 179 patients with PMM2-CDG showed normal or borderline IQ (Altassan et 
al 2018). Unfortunately, in milder cases, Tf IEF has shown to be mildly ab-
normal or normal also in older infants, and therefore diagnosis might be missed 
with screening (Vermeer et al 2007; Casado et al 2012). Still, despite the age 
and the clinical severity of four Estonian patients, in all, Tf IEF was strongly 
suggestive to CDG type I.  
 In family 1, the genotype p.Val231Met/p.Arg239Trp seems to relate to 
mild/moderate phenotype without relevant multisystem involvement in all 
siblings. In two older siblings, WISC showed normal cognitive development 
ranging from borderline (score 72) to low average (score 81). Despite that, 
motor development has been delayed in all three, and cerebellar hypoplasia in 
two older siblings. Central nervous system involvement and cerebellar hypo-
plasia are characteristic even in mild PMM2-CDG (Grunewald et al., 2001; 
Scott et al., 2014; Barone et al., 2015).  
Unfortunately, this genotype has not been reported in other patients to com-
pare the phenotypes. p.Val231Met is frequently found among patients with 
PMM2-CDG, and it is most frequently detected in combination with 
p.Arg141His. As mentioned earlier, this genotype causes a severe clinical 
phenotype (Matthijs et al., 1997; Matthijs et al., 2000; Grunewald et al., 2001; 
Barone et al., 2015). p.Arg239Trp has been described only once in combination 
with p.Phe157Ser, in which case the patients had either a mild-moderate or a 
moderate phenotype (Grunewald et al 2001). As p.Phe157Ser is considered to 
be severe variant with no residual activity (Vega et al 2011), p.Arg239Trp must 
be the milder variant with higher residual activity, which explains mild-
moderate phenotype of patients in family 1. Also, it might compensate the 
variant p.Val231Met, where encoded protein shows the 38% activity of wild-
type but is unstable (Pirard et al 1999). 
 In family 2, the genotype p.Arg123Gln/p.Val231Met relates to severe neuro-
visceral phenotype. p.Arg123Gln is severe variant with null residual activity 
(Vega et al 2011). The patients with this variant have often severe clinical 
picture, but mild phenotypes in combination with more functional PMM2 
variant (e.g. p.Cys241Ser) have been reported (Westphal et al 2001; Casado et 
al 2012). It is possible that p.Arg123Gln/p.Val231Met  cause similar phenotype 
as p.Arg123Gln/p.Arg141His as p.Val231Met is not mild enough to increase 
the activity of PMM2. 
 The summary of all four patients (patients 2, 3, 4 from family 1, and patient 
5 from family 2) detected in screening, and in comparison, also first PMM2-
CDG patient (patient 1) in Estonia are presented in Table 3. In conclusion, 
although the correlation between the genotype and the clinical phenotype may 
be controversial, based on the current data of Estonian patients it seems possible 
to predict the phenotype according to the variants present. Although not 
reported before, it seems likely that the genotype p.Val231Met/p.Arg239Trp 
locates in the milder, and p.Arg123Gln/p.Val231Met in the severe end of 
PMM2-CDG phenotype.                                  
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5.3. Prevalence of PMM2-CDG in Estonia (Paper II) 
5.3.1. Prevalence of PMM2-CDG according to  
population cohort data  
Similarly to other European countries, PMM2-CDG is the most common type 
of CDG diagnosed in Estonia. At the end of the screening period, PMM2-CDG 
was altogether diagnosed in five patients from three families. Interestingly, they 
all had variant p.Val231Met in one allele, and only one patient carried the most 
commonly reported p.Arg141His in PMM2. This urged us to find out whether 
the most common variant among Estonians was p.Val231Met. Also, we wanted 
to evaluate the presence of other PMM2 variants in our population and to 
calculate the expected frequency of PMM2-CDG in Estonia based on the data 
from population-based biopank (EGCUT). ECCUT includes the data and 
samples of almost 52,000 individuals. It represents 5% of the Estonian adult 
population reflecting closely the age, sex and geographical distribution of the 
Estonian population (Leitsalu et al 2015).  
 From WGS data of 2,244 individuals from EGCUT, all variants identified in 
the PMM2 were extracted. Possible novel disease-causing variants were not 
found. Altogether, 19 alleles listed as pathogenic according to HGMD were 
detected. Five different variants were identified: p.Arg141His (10 alleles), 
p.Val231Met (5 alleles), p.Arg239Trp (2 alleles), p.Val67Met (1 allele) and 
p.Thr237Arg (1 allele). Although the data from EGCUT did not allow us to 
fully exclude the possibility of the presence of biobank participants with 
variants in both alleles, it is highly unlikely. Observed carrier and allele fre-
quencies of PMM2 variants are shown in Table 4. 
 
 
Table 4. Observed carrier and allele frequencies of PMM2 variants of 2,244 individuals 
from EGCUT. 
 
PMM2 variant N of alleles Carrier frequency 
Allele 
frequency  
p.Arg141His 10 1/224 1/449 
p.Val231Met 5 1/449 1/898 
p.Arg239Trp 2 1/1122 1/2244 
p.Val67Met  1 1/2244 1/4488 
p.Thr237Arg 1 1/2244 1/4488 
Overall 19 1/118 1/236 
 
 
Homozygosity of p.Arg141His is considered lethal and has never been 
described in any patient (Matthijs et al 1998). In most cases, PMM2-CDG 
 55
patients are compound heterozygotes. Still, homozygosity of p.Leu32Arg, 
p.Lys51Arg, p.Tyr64Cys, p.Asp65Tyr, p.Pro113Leu, p.Phe119Leu, p.Val129Met, 
p.Asn216Ile, p.Tyr106Phe, p.Phe183Ser and p.Thr237Met has been reported 
(Matthijs et al 2000; Neumann et al 2003; Vermeer et al 2007; Najmabadi et al 
2011; Perez et al 2011; Kasapkara et al 2017; Schiff et al 2017). As some of the 
possible genotype recombinants have not been reported in any patient, we can-
not exclude that the homozygosity of variants other than p.Arg141His, or 
recombinants between the variants found in our population cohort are in-
compatible with life. Still, to calculate the expected disease frequency in Esto-
nian population, we assumed that only homozygosity of p.Arg141His was 
impossible. Based on modified Hardy-Weinberg equilibrium (r2+2qr), where q 
is the allele frequency of p.R141H (1/449) and r the combined allele frequency 
for other four identified variants (1/499), the expected frequency of the disease 
in Estonian population is 1/77,000. 
Only one report has previously estimated the PMM2-CDG frequency based 
on allele frequencies among healthy individuals (Schollen et al 2000). The 
frequencies of the p.Arg141His and p.Phe119Leu were studied among two 
normal populations consisting of 950 Dutch neonates and 420 Danish blood 
donors. Altogether, in Dutch, Flemish and Danish populations, the reported 
carrier frequency for p.Arg141His was 1/72 and expected disease frequency 
was 1/20,000. These numbers are much higher compared to our results. Even 
our combined carrier frequency for all variants (1/118) could not reach the 
carrier frequency of the most common variant in their study population. In the 
same paper, carrier frequency for other variants was estimated to be 1/300 to 
1/400, which in our population ranges from 1/448 to 1/2,244. 
There are reports about the prevalence of different PMM2 variants found in 
patients as well as overviews about genotypes in different populations. 
Although, p.Arg141His has always been the most commonly identified variant 
among Caucasian PMM2-CDG patients, other variants differ between countries. 
The selection of variants is wide, but in general their prevalence is rather low. 
Also, the genotypes are very variable. Variant p.Arg123Gln, which was not 
present in our population cohort, constitutes 1.9% of French, 3.9% of Spanish 
and 10% of Portuguese PMM2 variants present in patients. P.Val231Met is 
rather common among PMM2-CDG patients in United Kingdom and Portugal, 
but less prevalent in France, Italy and Spain (Imtiaz et al 2000; Le Bizec et al 
2005; Perez et al 2011; Perez-Cerda et al 2017). According to HGMD, 
p.Arg239Trp and p.Val67Met have been reported in few patients (Bjursell et al 
2000; Matthijs et al 2000; Grunewald et al 2001). Patients heterozygous for 
p.Arg239Trp have shown mild or moderate phenotype (Grunewald et al 2001; 
Vals et al 2017). p.Val67Met/p.Arg141His causes severe multisystem presenta-
tion with involvement of the nervous system (Erlandson et al 2001). 
p.Thr237Arg has been reported in French, Italians and Dutch. Genotype 
p.Val231Met/p.Thr237Arg caused severe neurovisceral syndrome and early 
death in an infant (Aronica et al 2005). On the contrary, p.Thr237Arg/ 
p.Cys241Ser caused multisystem disorder but borderline mental development 
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(Barone et al 2007). Similarly to p.Arg141His, p.Thr237Arg shows very low 
residual activity (Kjaergaard et al 1999). Theoretically it is possible, that the 
recombinant with p.Arg141His or homozygosity of p.Thr237Arg are lethal as 
one allele must retain its residual activity and this might influence our estimated 
frequency by making it a little bit lower (1/84,000). Still, at least one patient 
with genotype p. Arg141His /p.Thr237Arg has been described in French cohort, 
although the data about the phenotype was not presented. 
It is interesting that p.Phe119Leu was not presented in Estonian population 
cohort. This is the second most common variant among South-Scandinavian 
population (Kjaergaard et al 1998; Bjursell et al 2000).  
 
 
5.3.2. Prevalence of PMM2-CDG according to  
patient cohort data 
Several reports from different European countries describe allele frequencies of 
different PMM2 variants present in PMM2-CDG patients. In Estonia, diffe-
rences between allele frequencies based on population and patient cohorts were 
seen. One reason for this is probably a small number of molecularly confirmed 
patients, and it is possible that patients carrying p.Arg141His have been missed. 
Interestingly, in patient cohort, the p.Arg141His was only confirmed in one 
subject, whereas the second most common variant p.Val231Met in population 
cohort was present in all three families. Therefore, based on population data, 
our hypothesis about p.Val231Met being the most common variant in Estonia, 
was wrong. Another difference between two cohorts was the presence of 
p.Arg123Gln in one patient. This variant was inherited from French parent, 
which explains its absence in the Estonian population cohort.  
The five patients were born from 1997 to 2015. One of them is deceased and 
one has reached adulthood. During 2011 census, 1.29 million enumerated 
residents were counted in Estonia and 18.4% (approximately 237,000) of them 
were children, defined as age less than 18 years. This makes the current pre-
valence of PMM2-CDG for the whole population (four alive patients) 1/322,000 
(95% CI 1/117,000–1/1,007,000) and for the children less than 18 years age 
group (three patients), 1/79,000 (95% CI 1/25,000–1/306,000).  
If we compare the estimated frequency 1/77,000 with Estonian population 
size and its age-specific distribution, approximately 16 people, including three 
children, should have PMM2-CDG. The calculated prevalence in the less than 
18 years age group is 1/79,000, which is similar to the expected frequency of 
PMM2-CDG in Estonia based on population allele frequencies. On the other 
hand, the current prevalence based on diagnosed patients is much lower 
(1/322,000). It is possible that the actual prevalence is higher since the disease 
has not been diagnosed for instance in any adult patient. PMM2-CDG might be 
under-diagnosed among adults as well as older children as some of them either 
might be deceased, or present mild or stable phenotype. In addition, although 
the availability of different diagnostic tests is significantly increased in Estonia, 
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congenital metabolic diseases, including CDG, are less likely considered and 
investigated among the adult patients. It is possible that adults are not under 
regular follow-up (e.g. people in special care institutions) or their families are 
either not aware or interested in the new possibilities of metabolic and mole-
cular studies. 
 
 
5.4. Clinical phenotype of SLC35A2-CDG (Paper III) 
5.4.1. Estonian patient with SLC35A2-CDG 
5.4.1.1. Clinical description 
The male patient was born at term (38+6 gestational weeks) from uneventful 
pregnancy. He needed tactile stimulation and additional oxygen after birth due 
to perinatal hypoxia (Apgar scores 4/8/8). His birth weight was 2986 gr (<50 
ct), length 45.5 cm (3 ct) and head circumference 34 cm (50 ct). During the 
second half of the first year of life he needed physiotherapy due to spastic 
diplegia. At the age of 18 months he was investigated because of cranio-
synostosis. At that time, his motor and cognitive development was in accor-
dance with the age of 12 months. He preferred to crawl but also made some 
steps. His muscular tone was decreased. He showed turribrachycephaly, small 
umbilical hernia, tongue-tie, labial frenulum, hypertelorism, small contact nose, 
long philtrum, and small mandible. On growth chart both, weight and height 
were less than 3 ct but head circumference was within normal limits. 3D 
computed tomography showed isolated synostosis of sagittal suture (Figure 8J). 
At the age of 22 months, the brain MRI showed short corpus callosum and 
delayed myelination of the white matter with patchy high signal intensity 
lesions in the periventricular white matter, in medial globus pallidus, in 
posterior mesencephalon, in medial cerebellar peduncule, and in dentate nucleus 
(Figure 8A-I). Leigh disease was suspected. This led to expanded metabolic 
investigations, including Tf IEF. Biochemical studies showed increase of 
aspartate aminotransferase (AST) and thyreoglobulin, and decreased ATIII. His 
EEG was normal. 
At the age of 3 years, adenoidectomy was performed and after the procedure 
the bleeding was more pronounced than usual. His craniosynostosis did not 
need the surgical correction. At the moment he is ambulatory and shows mild 
developmental and speech delay. He is attending in special day care. At the age 
of 5 years and 1 month his height was 94.9 cm (0.1 ct, -3 SD) and weight 14.2 
kg (1.02 ct, -2.32 SD). The patient is under regular follow-up by the clinical 
geneticist, ophthalmologist, endocrinologist, psychologist and speech therapist.  
The patient has been treated with alimentary oral Gal since the age of 27 
months. The starting dose was 0.5 g/kg/day in addition to dietary Gal 1 
g/kg/day, and increased to 1–1.5 g/kg/day. After six months of therapy, the 
activity and development of the patient showed improvement, the child was 
more alert. Also, the level of ATIII increased, and thyreoglobulin normalized, 
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whereas AST remained slightly elevated. Alternating levels of ATIII and 
thyreoglobulin have reflected the compliance to the treatment. 
Figure 8. The brain MRI of Estonian patient with SLC35A2-CDG. T2 weighted image 
and diffusion weighted image show no significant atrophy but delayed myelination with 
patchy high signal intensities in the periventricular white matter (A and E), in medial 
globus pallidus (B and F), in posterior mesencephalon (C and G) and in medial cere-
bellar pedunculi (D and H), short corpus callosum (I), craniosynostosis of sagittal suture 
(J), and normal spectroscopy (K) (Vals et al. 2018). 
 
 
5.4.1.2. Glycosylation and molecular studies 
The hypothesis of mitochondrial Leigh disease was based on a brain MRI 
finding, whereas magnetic resonance spectroscopy as well as blood lactate, 
pyruvate, and ketones were within normal values. Tf IEF type 2 profile, first 
done at the age of 23 months, suggested glycosylation disorder. Quantification 
of sialotransferrins revealed increase of di- and trisialotransferrin (10.9%, 
normal limits 3.3–7.6%, and 19.3, normal limits 4.9–10.6%, respectively), and 
slight decrease of tetrasialotransferrin (44.5%, normal limits 47.6–62.7%). 
Asialotransferrin was normal (2%, normal limits 0–3.2%) and monosialo-
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transferrin was on the upper normal limit (4.1%, normal limits 0–5%). Normal 
ApoC-III isoforms excluded combined N- and O-glycosylation defect. 
Glycoprofiling of intact Tf with quadrupole time-of-flight MS showed the 
increased loss of Sia (21%, normally <5–6%) but also several minor glycan 
peaks showing the lack of Gal and Sia residues (Figure 9). NGS of a large gene 
panel revealed defects neither in genes related to CDG nor mitochondrial 
diseases. Trio WES revealed a novel de novo hemizygous variant c.670C>T, 
p.Leu224Phe in SLC35A2 located on X-chromosome. This variant was 
confirmed by Sanger sequencing. SLC35A2 was not included in the previously 
performed gene panel. 
 
 
 
 
Figure 9. Serum Tf quadrupole time-of-flight MS of the Estonian patient with 
SLC35A2-CDG (with the permission of Dirk Lefeber). 
 
 
5.4.2. International patients with SLC35A2-CDG 
The comparison of the phenotype between Estonian patient and patients in the 
international cohort is shown in Table 5. International cohort included three 
males and eleven females with current ages 4 to 28 years. One of these patients 
was deceased. All showed global DD. Only three were able to ambulate. 
Muscular hypotonia was present in all. Epilepsy was also frequent (12/14), and 
often hypsarrhythmia was described in EEG. Many patients had feeding 
difficulties and required tube feeding. Ophthalmologic findings were frequent: 
9/14 had either strabismus and/or refractive error, and 3/14 had cerebral visual 
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impairment. Ten out of thirteen had short stature. Unspecific dysmorphic 
features were described in 10/14. Musculoskeletal anomalies were common 
(e.g. contractures, deformities of the lower limbs, scoliosis).  
 The brain MRI was available in 8/14, and was performed at the ages of 10 
months to 18 years. In two patients, repeated MRIs were available, which did 
not show the progression of the radiological findings. Unlike Estonian patient, 
many patients showed cerebral, cerebellar, pons and/or brainstem atrophy. All 
patients had short corpus callosum. Delayed myelination was seen in 6/8. White 
matter atrophy was present in 6 patients. In all, patchy hyperintensities in supra- 
and subtentorial white matter were seen. 
 
 
Table 5. The phenotype of the patients in SLC35A2-CDG cohort. 
 
  Estonian patient 
International 
cohort Summary 
Clinical findings  
Global developmental delay + 14/14 15/15 
Muscular hypotonia  + 14/14 15/15 
Seizures  - 12/14 12/15 
Hypsarrhythmia or findings 
consistent with epileptic 
encephalopathy in EEG   
9/11 9/11 
Opthalmologic findings - 13/14 13/15 
Short stature            +             10/13 11/14 
Musculoskeletal abnormalities + 9/14 10/15 
Abnormal N-glycosylation of Tf + 8/14 9/15 
MRI findings 
Cerebral atrophy - 7/8 7/9 
Cerebellar - 5/8 5/9 
Brain stem and/or pons atrophy - 4/8 4/9 
Thin corpus callosum - 7/8 7/9 
Short corpus callosum + 8/8 9/9 
White matter atrophy - 6/8 6/9 
Delayed/hypomyelination + 6/8 7/9 
High signal intensity lesions of 
white matter + 8/8 9/9 
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Similarly to Estonian patient, isolated mild increase of AST was seen in half, 
and some patients showed changes in coagulation markers. CDG screening with 
Tf isoform analyses or Tf MS was abnormal in 8/14. Tf IEF showed type 2 
profile and Tf MS characteristic loss of Gal. Normalization of Tf IEF in early 
infancy was reported in two patients, whereas one patient showed the worsening 
of glycosylation studies.  
 Overall, fourteen different variants in SLC35A2 were presented. All variants 
presented in the cohort affected both transcripts, UGT1 and UGT2. Eleven 
patients had missense variant in SLC35A2 gene. One had in-frame deletion, and 
two had frameshift deletions. The majority of variants appeared de novo. 
However, one patient had inherited the variant from the mother. Mosaicism was 
only reported in one male and one female patient, but often, mosaicism was not 
studied in other tissues. X-inactivation was studied in three females. One patient 
showed skewed X-inactivation in blood leukocytes, whereas in the second 
female, skewed pattern was only seen in buccal cells and skin fibroblasts. In the 
third female, X-inactivation was random in blood leukocytes.  
 
  
5.4.3. Challenges in the diagnosis of SLC35A2-CDG 
The phenotype of fifteen patients with SLC35A2 variant shows that SLC35A2-
CDG affects mainly and often severely the nervous system, and the reported 
symptoms are similar to previous reports (Kodera et al 2013; Ng et al 2013; 
Dorre et al 2015; Kimizu et al 2017; Westenfield et al 2018; Yates et al 2018).  
All the patients in the cohort had global DD and hypotonia, the majority was 
non-ambulatory, and epilepsy was frequently present.  
As it was seen also in our international cohort, the majority of reported 
patients so far are females. No clear correlation between the gender and severity 
of symptoms, including abnormal glycosylation studies, was seen. SLC35A2-
CDG is an X-linked disorder and therefore, a more severe phenotype might be 
expected in males. One hypothesis is that in males, mosaicism would be 
necessary for survival. The findings in our cohort do not support that, as only 
one male presented with mosaicism. In addition, non-mosaic Estonian male 
patient seemed to have the mildest phenotype in the cohort. Nevertheless, he 
has presented continuously abnormal glycosylation, which also makes difficult 
to associate the degree of clinical severity with the presence of abnormal glyco-
sylation.  
The clinical phenotype of SLC35A2-CDG is rather unspecific, and the 
diagnosis based on clinical symptoms, is difficult. In addition, the main chal-
lenge in diagnosing SLC35A2-CDG is the absence of abnormal Tf screening in 
some patients. Tf isoform analyses may have diagnostic value in early child-
hood (Ng et al 2013). As in other reports, the collected data in our cohort 
showed that glycosylation can improve, but also worsen over time, or be normal 
at the time of the first study. In case of abnormal screening, the diagnosis of 
SLC35A2-CDG is not challenging. Tf MS shows characteristic glycan profile 
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and disorder can be confirmed either with SLC35A2 sequencing or gene panel. 
In many reported patients, including seven in our cohort, SLC35A2 variants 
were first detected by WES, which was followed by glycosylation studies that 
were normal in six. This raises the question whether all patients with SLC35A2 
variant have CDG. Indeed, some CDG genes can cause divergent disorders (Ng 
and Freeze 2018), but all the reported patients with SLC35A2 variant show a 
similar clinical phenotype. The hypothesis is that normalization of glycosylation 
might be associated with somatic mosaicism in boys, or skewed X-inactivation 
of mutated alleles in girls, which might lead to negative selection of mutated 
cells in visceral organs such as liver. Another possibility is that such patients 
have shown or will show abnormal glycosylation in different ages, but at the 
time of screening glycosylation has been normal. In future, functional studies 
may become helpful in confirming the pathogenicity of SLC35A2 in the case of 
negative screening. Functional assays of UGT in the fibroblasts of SLC35A2-
CDG patients, and UGT-deficient cell lines showed increased binding of 
glycans to the lectins indicating incomplete galactosylation (Ng et al 2013; 
Dorre et al 2015). At the moment these studies are not routinely available.  
Therefore, presently the diagnostic approach to patients with new SLC35A2 
variant and normal glycosylation (including normal Tf MS) includes careful 
pathogenicity classification that should follow internationally acclaimed variant 
interpretation guidelines like those published by ACMG (Richards et al 2015). 
As previously mentioned, among six patients, SLC35A2 variants were not 
supported by abnormal glycosylation profiles at the time of screening. All de 
novo variants were absent in population databases, and according to ACMG 
classification, they were considered likely pathogenic. One patient had inherited 
the variant from his unaffected mother, and it was considered as the most 
probable cause for the symptoms. All six patients have similar severe neuro-
logical symptoms, and many are treated with dietary galactose, which has 
previously been shown to improve seizure activity as well as Tf glycosylation in 
a female patient with SLC35A2-CDG (Dorre et al 2015).  
Since a growing number of patients is reported with SLC35A2 variants, 
similar genotypes have appeared. New patients with similar genotypes could 
add valuable information of the glycosylation status, and also about possible 
genotype-phenotype correlations in the future. Together with the subject in our 
cohort, there are at least two females and one male with the variant p.Val331Ile, 
and interestingly, they all did not have seizures. In a male and female with a 
variant p.Val331Ile, glycosylation showed improvement over time (Ng et al 
2013; Westenfield et al 2018). Additionally, two females with p.Ala88Pro, one 
male and one female with p.Ser308Phe have been described (Bruneel et al 
2018; Vals et al 2018; Yates et al 2018). In our cohort, the patients with 
previously mentioned three genotypes showed abnormal glycosylation. Un-
fortunately so far, there are no reports presenting the patients with similar 
genotypes to the six patients with normal glycosylation in our cohort.  
It is also important to remember that in addition to diagnostic pitfall due to 
false-negative screening, gene sequencing studies might also miss the variants, 
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and sometimes, abnormal glycosylation profile helps to identify the variant as 
was also seen among two patients in our cohort (Kodera et al 2013; Ng et al 
2013). Additional studies are needed to clarify the different aspects of 
SLC35A2-CDG such as causes for variable glycosylation status and possible 
positive effect of dietary galactose. 
 
 
5.5. Novel type II CDG caused by  
homozygous variant in STX5 
5.5.1. Clinical description of two siblings with CDG-IIx 
The male proband 1 (IV:9 in Figure 10) was born prematurely (premature 
rupture of membranes and acute chorioamnionitis) to a 26-year-old gravida 9 
para 3 woman on 29th gestational week. His birth weight was 1380 gr (0 SD), 
length 36.2 cm (-2 SD) and head circumference 29.5 cm (+2 SD). Apgar scores 
were 3, 6, and 7. During the pregnancy, fetal anatomical ultrasound scan 
showed shortening of long bones, bilateral clubfeet and flection contracture of 
both knees.  
He was admitted to neonatal intensive care unit due to prematurity and 
respiratory distress. The following dysmorphic features were observed: macro-
cephalic abnormal skull configuration with asynclitism, prominent forehead, 
mild exophthalm, hypertelorism, short contact nose, high nasal bridge, long 
philtrum, sublingual cyst, dysmorphic ears, edematous skin, excessive skin on 
neck, bilateral simian lines, short extremities (proximal>distal), narrow thorax 
and bilateral clubfeet. An echocardiography revealed ventricular septal defect. 
The ultrasound scan showed hepatomegaly, agenesis of the left kidney, and 
hyperechogenicity in periventricular and thalamic areas of the brain, which 
might refer to hypoxic-ischemic brain injury. 
After birth, the main clinical problem was progressive liver failure with 
coagulation abnormalities (ATIII 6% and protein C 20%), hypercholesterolemia 
(8.5 mmol/L), hyperbilirubinaemia (480 μmol/L, direct bilirubin 180 μmol/L) 
and – hyperammonaemia (180 μmol/L), high AST (360 U/L) and alkaline 
phosphatase (1611 U/L).  In addition, he had hyperinsulinemic (33.5 mU/L) 
hypoglycemia, lower level of TSH (1.36 mU/L) and free thyroxine (8,1 pmol/L), 
very low IGF-I (<25 μg/L) and anemia. Very long chain fatty acid analysis 
showed slightly higher hexacosanoate (C26:0, 1.58 μmol/l, range 0.45– 
1.32 μmol/l), and hexacosanoate and docosanoic acid ratio (C26:0/C22:0)  
0.02 μmol/l (0.01–0.02 μmol/l) possibly due to secondary changes. 
The child died on 25th day of life due to multiorgan failure. Autopsy showed 
hyperemia of internal organs, hepatomegaly with stage 3 to 4 liver fibrosis, 
agenesis of the left kidney, ventricular septal defect, ischemic necrosis and 
perforation of small intestine with mild peritonitis, infant respiratory distress 
syndrome stage III and pulmonary edema, and suggestive pathohistological 
features of chondrodysplasia. 
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Figure 10. The pedigree of siblings with CDG-IIx. 
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Female proband 2 was the elder sibling of proband 1 (IV:8 in Figure 10). 
The pregnancy was medically aborted on the 21st week of pregnancy due to 
clinical suspicion of achondroplasia, as the shortening of long bones was seen in 
the fetal ultrasound scan. Fetus had short extremities, which was more evident 
in legs (proximal>distal), bilateral clubfeet, ulnar deviation of wrists, 
clinodactyly of fifth finger, and excessive skin on neck. She had a rather similar 
facial phenotype to patient 1 – high forehead, mild exopthalm, high nasal 
bridge, short nose, long philtrum, and dysmorphic right ear. The weight was 
332 grams (in accordance with 20–21 gestational weeks) and length 20.5 cm (in 
accordance with 17–18 gestational weeks). In autopsy, bilateral hydronephrosis 
and sacral lordosis were seen. Otherwise, the macroscopic and histological 
findings of the organs were in accordance with gestational age.  
In the family history, the mother has one healthy son (IV:2 in Figure 10). 
Three pregnancies were medically interrupted (IV:1, IV:4, and IV:8), two of 
them on the 20th to 21st week of pregnancy due to abnormal ultrasound scan 
findings of fetuses (IV:4 and described IV:8). In addition, the mother had three 
spontaneous abortions (IV:5, IV:6, and IV:7). Male sibling IV:3 died immedia-
tely after birth. As he was born abroad, we do not have any clinical information 
about him. 
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5.5.2. Glycosylation and molecular studies 
Tf IEF of proband 1 serum showed abnormal type 2 profile with increased 
asialo- and trisialotransferrin and decreased tetrasialotransferrin. Quadrupole 
time-of-flight MS of intact Tf revealed a loss of Sia and many additional 
abnormal glycan structures, with a peculiar transferrin having a short mannose 
containing glycan which has not been seen in any other known type of CDG 
(Figure 11). IEF of ApoC-III revealed a strongly abnormal profile with marked 
increase of ApoC-III0 (56%, normal range 0.2–4.5%), and decreased ApoC-III1 
and ApoC-III2 suggesting combined N- and O-glycosylation defect. 
 
Figure 11. Glycosylation studies of proband 1. A. Abnormal type 2 Tf IEF. B. 
Quadrupole time-of-flight MS of intact Tf (with the permission of Dirk Lefeber). C. 
Quadrupole time-of-flight MS of total serum N-glycans (with the permission of Dirk 
Lefeber). 
 
In proband 2, fetal karyotype was 46,XX. Variant analysis of FGFR3 gene and 
other skeletal dysplasias was normal. 
Chromosomal microarray analysis revealed multiple LCSH (>5 Mb) 
distributed across the entire genome of probands 1 and 2 (Figure 12). The 
percentage of homozygosity was ~8.3% and ~5.3% for probands 1 and 2, 
respectively, which points to a probable parental consanguinity. However, the 
parents of the described probands do not know that they are related and 
according to the recommendations of ACMG, speculations on a specific 
relationship should be avoided (Rehder et al 2013).  
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Figure 12. Multiple LCSH distributed across the entire genome in proband 1 (with the 
permission of Olga Fjodorova, previous name Žilina). 
 
Taking into account the similar clinical phenotype of proband 1 and 2, LCSH 
were further compared to find overlapping regions (Table 6). The candidate 
gene for this novel type of CDG was already found in 2014, when a homo-
zygous c.163A>G (p.Met55Val) variant in STX5, located on chromosome 11, 
was detected in one LCSH region by WES. Sanger sequencing analysis showed 
that identified variant was in homozygous state in both affected probands and 
heterozygous in the parents. The variant is absent from gnomAD.  
 
Table 6. Overlapping chromosomal regions of proband 1 and 2. STX5 gene locates on 
chromosome 11q12.3 (with the permission of Olga Fjodorova, previous name Žilina). 
Chromosome Start Position (bp) End Position (bp) Length (bp) 
2p22.1-p21 41 051 123 47 273 511 6 222 389 
5q22.3-q23.2 113 940 187 123 909 500 9 969 314 
11p15.2-p13 15 745 640 32 583 695 16 838 055 
11p13-p11.12 33 423 590 51 530 241 18 106 651 
11q11-q22.1 55 091 268 102 091 632 47 000 364 
 
 
STX5 encodes a protein STX5, which is a member of SNAREs family, and 
important in the intra-Golgi vesicle transport, docking and fusion. Vesicles 
carry Golgi resident proteins, some of which are important in glycosylation pro-
cess. As defects in COG complex subunits affect additionally the normal 
functioning of other components in the vesicle trafficking machineries such as 
SNAREs, one might assume that similarly, the defects in any family member of 
SNAREs have the same effect on the normal function of COG complex. There-
fore, it is possible that defective STX5 protein causes Golgi disorganization, 
and leads to disrupted intra-Golgi trafficking and abnormal protein glycosyla-
tion. Notably, some overlapping of the symptoms (liver and skeletal involve-
ment, and dysmorphism) is seen between described two siblings and patients 
with COG-CDG, which also supports the assumption that complexes regulating 
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Golgi trafficking and homeostasis complete each other. Although multiple lines 
of computational evidence support a deleterious effect of the p.Met55Val 
variant in STX5, functional studies are needed to prove whether this variant is 
the definite cause of the new type of CDG. These studies could also demonstra-
te the exact function of STX5 in the glycosylation pathway.  
The introduction of Tf IEF in our practice led to unexpected discovery of 
novel type II CDG, which might be caused by homozygous variant in STX5, and 
which affects multiple glycosylation pathways. Although the functional con-
firmation studies are still ongoing to prove the pathogenicity of the variant, it is 
possible that it impairs severely the function of encoded protein. Both probands 
shared common clinical characteristics such has distinct facial features, 
shortened extremities and anomalies of the limbs. How this defect would impact 
the development, and whether this type of CDG is lethal, remains unknown, but 
progressive neonatal liver failure alone poses a great challenge to clinicians.  
Unfortunately, we have not found any other patients in the world with a 
similar phenotype and STX5 defects, although we have presented this case in the 
conference of The European Society of Human Genetics, as well as at the 
meeting of European Metabolic Group. Moreover, we added this STX5 variant 
also to GeneMatcher database (Sobreira et al 2015), but did not find a match. 
The clinical cases of our patients highlight the difficulties in defining a new 
type of CDG that is based on a single family. Still, we plan to publish this case 
after finishing this PhD study. 
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6. CONCLUSIONS  
1.  The results of CDG screening among Estonian patients during a three-year 
screening period were reported (Paper I and IV).  
1.1  Transferrin isoelectric focusing is simple and efficient method to detect 
most defects affecting N-glycosylation pathway. 
1.2  We confirmed CDG in six patients among 1230 subjects screened. 
1.3  The most frequent CDG in Estonia is PMM2-CDG, which is similar to 
other populations.  
1.4  We improved markedly the awareness of CDG among Estonian clini-
cians. 
2.  The clinical phenotype and molecular findings of four patients with PMM2-
CDG from two families were evaluated (Paper I). 
2.1  The phenotypic features of Estonian PMM2-CDG patients are similar to 
previously described patients. 
2.2  We detected a family with three siblings who show a mild neurological 
phenotype with normal-borderline cognitive development, which has 
previously been seldom described. 
2.3  Among PMM2-CDG patients, the most common variant in PMM2 was 
p.Val131Met, and not p.Arg141His as seen in other populations. 
3.  The expected frequency of PMM2-CDG based on Estonian population data, 
and the prevalence of PMM2-CDG based on diagnosed PMM2-CDG 
patients in Estonia were reported. 
3.1 Five different heterozygous variants in PMM2 were identified in Esto-
nian normal population. The most frequent variant is p.Arg141His with 
carrier frequency 1/224; carrier frequency for p.Val131Met is 1/449.  
3.2  The expected frequency of PMM2-CDG based on Estonian normal 
population data is 1/77,000. We demonstrated that the population cohort 
data give useful new information about the epidemiology of the PMM2-
CDG. 
3.3  Based on the patient population data, the prevalence of PMM2-CDG for 
the age group 0 to 17 years is 1/79,000. 
4.  The clinical phenotype and molecular findings of 15 international patients 
with SLC35A2-CDG were characterized and compared (Paper III). 
4.1  The diagnosis of SLC35A2-CDG is very challenging.  It presents as the 
non-specific neurological syndrome with global developmental delay, 
hypotonia, seizures, and the brain MRI changes such as cerebral and 
cerebellar atrophy, delayed myelination of white matter and short 
corpus callosum, together with dysmorphic features and short stature. 
4.2  A negative transferrin isoform screening does not exclude SLC35A2-
CDG.  
4.3  A diagnostic approach to patients with new SLC35A2 variant but 
normal glycosylation screening is proposed. First, the glycosylation 
profile should be assessed with high-resolution mass spectrometry of 
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intact transferrin. If the profile is diagnostic then the rare variant found 
could be considered as pathogenic. If the profile is normal, a careful 
assessment of patients’ phenotype should be combined with a careful 
pathogenicity classification that follows internationally acclaimed 
variant interpretation guidelines like those published by American 
College of Medical Genetics and Genomics classification.  
5.  The clinical phenotype and molecular findings of a patient with a novel type 
II CDG likely caused by homozygous variant in STX5 gene are presented. 
5.1  Index patient presented multisystem clinical CDG features including 
dysmorphy, hepatomegaly, liver fibrosis and failure, skeletal anomalies 
(short extremities and clubfeet), renal anomaly, coagulopathy, and 
endocrine disturbances.  
5.2  Transferrin isoelectric focusing performed on the fifth day of life 
revealed markedly abnormal type 2 profile with increased asialo- and 
trisialotransferrin and decreased tetrasialotransferrin. This led us to 
continue studies towards CDG diagnosis, which was the main cause of 
the symptoms in the patient. 
5.3  The combination of different genomic analyses revealed the homo-
zygous variant in STX5 gene, which impairs Golgi trafficking and 
normal glycosylation. 
5.4  It is very likely that the identified variant in STX5 gene is pathogenic. 
The functional studies are presently at work. 
 
The introduction of CDG screening in clinical practice in Estonia showed that 
the isoelectric focusing of serum transferrin is an effective method to detect 
CDG among patients. It offers relatively fast primary information to clinicians, 
and if negative, CDG is likely to be excluded. The isoelectric focusing of serum 
transferrin is now routinely used in our clinical practice, and we have diagnosed 
two new patients with CDG. 
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8. SUMMARY IN ESTONIAN 
Kaasasündinud N-glükosüülimise haigused Eestis 
 
Sissejuhatus 
Kaasasündinud glükosüülimise haigused (KGH) moodustavad kiirelt areneva 
ainevahetushaiguste grupi ning on põhjustatud valkude ja lipiidide primaarsest 
hüpoglükosüülimisest. Normaalne glükosüülimisprotsess tagab paljude sekre-
toorsete, membraansete ja rakusiseste valkude häireteta funktsioneerimise.  
Alates haiguse esmakirjeldusest 1980. aastal on kirjeldatud vähemalt 125 
erinevat KGH (Ng and Freeze 2018). KGH alatüüpe tähistatakse põhjusliku 
geeni sümboliga, millele järgneb lühend CDG (congenital disorders of glyco-
sylation). Kõige sagedamini esineb valkude N-glükosüülimise defekte, mis 
päranduvad peamiselt autosoom-retsessiivsel teel. Sünteesi on haaratud paljud 
ensüümid ja teised vajalikud valgud, mille funktsiooni ja seeläbi N-glükosüü-
limist mõjutavad neid kodeerivate geenide mutatsioonid. Lisaks vajab glüko-
süülimisprotsess normaalseks kulgemiseks rakuorganellide õiget struktuuri ja 
sobivat mikrokeskkonda.  
N-glükaanide sünteesis eristatakse kolme põhietappi: nukleotiididega seotud 
monosahhariidide süntees, lipiidiga seotud oligosahhariidi kokkupanek ja 
glükaani töötlemine. Süntees toimub kindlas järjekorras tsütosoolis, endo-
plasmaatilises retiikulumis (ER) ning Golgi kompleksis (GK). Tsütoplasmas 
liidetakse lipiidse kandja, fosforüleeritud dolihhooli külge kaks N-atsetüül-
glükoosamiini (GlcNAc) molekuli ja viis mannoosijääki (Man). Struktuur 
pööratakse flipaasi toimel ER-i valendikku, kus seda pikendatakse veel nelja 
Man-i ning kolme glükoosimolekuliga. Seejärel kantakse oligosahhariid lipiid-
selt kandjalt üle valgu koostises olevale aminohappele asparagiin ning algab 
glükaani töötlemine. Protsess algab ER-is ja lõppeb GK-s. Oligosahhariidilt 
eemaldatakse ükshaaval monosahhariidide jäägid, kuni järele jääb kaheharuline 
kolmest Man-ist koosnev struktuur. Kummagi haru külge lisatakse üks GlcNAc, 
üks galaktoosi (Gal) ning üks siaalhappe molekul ja seejärel on glükoproteiin 
valmis. Olenevalt glükoproteiinist võib glükaanil olla ka rohkem harusid. 
N-glükosüülimise defektide peamiseks skriiningmeetodiks on seerumi 
transferriini isoelektriline fokuseerimine (IEF), millega hinnatakse skriinitava 
patsiendi transferriini isovorme ja mis võib anda viite KGH esinemisele kuni 48 
alatüübi puhul, mis otseselt või kaudselt mõjutavad N-glükosüülimist (Jaeken 
and Peanne 2017). Eristatakse kahte tüüpi profiile sõltuvalt sellest, milline N-
glükosüülimise sünteesi etapp on häirunud. Skriiningu puuduseks on see, et 
esineda võivad näiteks patsiendi vanusest või KGH alatüübist tingitud vale-
negatiivsed või sekundaarsest hüpoglükosüülimist põhjustavatest seisunditest 
(näiteks galaktoseemia, infektsioon) tingitud vale-positiivsed tulemused. Eestis 
on IEF interpreteerimine kvalitatiivne ning subjektiivne.  
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Olenevalt skriiningul leitud profiilist ja patsiendil esinevatest sümptomitest 
järgneb positiivsele skriiningule kas kindla geeni sekveneerimine, apolipo-
proteiin C-III IEF, glükaani struktuuride hindamine massispektromeetria 
meetodil ja/või ensümaatilised uuringud. Diagnoosi kinnitavad molekulaarsed 
uuringud (kindla geeni sekveneerimine, ülegenoomsed uuringud). Võimalik on, 
et KGH diagnoositakse ülegenoomsete uuringute tulemusel ilma biokeemiliste 
kõrvalekallete toetuseta, mis teeb uute mutatsioonide patogeensuse hindamise 
keeruliseks. Seetõttu on oluline funktsionaalsete lisauuringute olemasolu KGH 
kinnitamiseks. 
Sõltuvalt KGH alatüübist võivad kliinilised sümptomid olla tihti kattuvad ja 
mittespetsiifilised ning sama alatüübi puhul võib nende raskusaste olla patsien-
tide lõikes erinev. Sümptomid haaravad peaaegu alati närvisüsteemi (üldine 
arengu hilistumine erinevas raskusastmes, lihashüpotoonia, epilepsia, ataksia ja 
aju väärarendid), kuid kaasuda võivad ka teiste organite funktsioonihäiretest 
põhjustatud sümptomid (maksapuudulikkus, kardiaalsed ja oftalmoloogilised 
probleemid, skeletianomaaliad, hüübimishäired ja sagedased infektsioonid). 
Paljude alatüüpide puhul on kirjeldatud vaid üksikuid patsiente. Põhjuslik ravi 
on olemas vaid mõnele KGH alatüübile (näiteks MPI-CDG) ning peamiselt on 
ravi sümptomaatiline ning toetav. 
Kõige sagedasem KGH alatüüp on PMM2-CDG, mille hinnanguline esi-
nemissagedus mutatsioonikandluse põhjal on 1/20,000 (Schollen et al 2000). 
Seda alatüüpi põhjustavad erinevad mutatsioonid PMM2 geenis, mis kodeerib 
ensüüm fosfomannomutaasi (PMM2). PMM2 osaleb Man-i sünteesis, mis on 
glükosüülimisprotsessis väga oluline substraat. Ensüümi aktiivsuse vähenemise 
tagajärjel on valkude küljes tavapärasest vähem glükaane või puuduvad need 
üldse. Klassikalise PMM2-CDG korral esinevad haigetel nii düsmorfsed 
tunnused (rinnanibude sissetõmme, omapärased rasvapadjandid), mitme organ-
süsteemi haaratus (näiteks seedetrakt ja hüübimissüsteem) kui ka neuro-
loogilised sümptomid (üldine arengu hilistumine, lihashüpotoonia ja ataksia). 
Klassikaline multisüsteemne fenotüüp on iseloomulik eeskätt varajases imiku-
eas. Edaspidi domineerib närvisüsteemi haaratus, kuid haigus ei progresseeru. 
Vaatamata haiguse raskusastmele on kõikidele haigetele iseloomulik närvi-
süsteemi haaratus ning väikeaju atroofia. PMM2-CDG puhul on suremus 9–
15% (Perez-Cerda et al 2017; Schiff et al 2017). Enamik patsiente on PMM2 
mutatsioonide suhtes liitheterosügoodid. Euroopa rahvastiku hulgas on kõige 
sagedasem mutatsioon p.Arg141His, mille puhul PMM2 aktiivsus on nulli-
lähedane. Fenotüübi raskusastme määrab sageli kergem mutatsioon. Siiski ei 
pruugi sarnase genotüübiga patsientide fenotüüp sarnaneda ja oletatakse, et 
haiguse raskusastmes mängivad rolli ka teised faktorid. 
SLC35A2-CDG on KGH alatüüp, mis pärandub X-liitelisel teel. Geen 
SLC35A2 kodeerib Gal-i transporterit, mis viib Gal GK-sse ja mille puudumisel 
kannavad valgud enda küljes ehituslikult puudulikke glükaanistruktuure. 
SLC35A2-CDG puhul võib skriining olla negatiivne, mistõttu paljud haiged on 
diagnoositud ülegenoomsete uuringute abil. Haigetele on iseloomulik peamiselt 
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raskeloomuline üldise arengu hilistumine ja epileptiline entsefalopaatia. Haigete 
sümptomeid on leevendanud ravi Gal-iga (Dorre et al 2015). 
STX5 geeni pole siiani KGH-ga seostatud. STX5 reguleerib vesiikulite 
vahendatud valkude transporti ja liitumist sihtmembraaniga. STX5 lokaliseerub 
trans-Golgis ja moodustab komplekse teiste glükosüülimises oluliste valkudega, 
mis aitavad luua sobivat GK keskkonda ja ehitust. 
 
 
Töö eesmärgid 
1.  Juurutada Eestis KGH diagnostikaks transferriini isoelektriline fokuseeri-
mine ja hinnata skriiningu efetkiivsust. 
2.  Hinnata Eesti PMM2-CDG diagnoosiga patsientide genotüüpi ja fenotüüpi. 
3.  Hinnata populatsiooni ja diagnoositud patsientide andmete põhjal PMM2-
CDG eeldatavat sagedust ning levimust Eestis. 
4.  Iseloomustada Eesti SLC35A2-CDG patsiendi feno- ja genotüüpi ja võrrelda 
seda 14 rahvusvahelise patsiendi feno- ja genotüübiga. 
5.  Esitleda uudse glükosüülimisdefektiga patsienti, kelle puhul põhjustab 
defekti tõenäoliselt STX5 homosügootne mutatsioon. 
 
 
Uuringugruppide, patsientide ja meetodite lühikirjeldus 
KGH skriiningu periood kestis ajavahemikul 01.06.2012–30.06.2015. Skrii-
ningu meetodina kasutati transferriini IEF-i. Et suurendada võimalike KGH-ga 
patsientide hõlmatust, teostati skriining kõigile ainevahetushaiguste kahtlusega 
patsientidele, kelle seerum saadeti SA Tartu Ülikooli Kliinikumi ühendlabori 
kliinilise geneetika keskusesse erinevate ainevahetushaiguste uuringuteks nii 
Tallinna kui ka Tartu haiglatest. Skriiningut teostati 1230 patsiendile. Positiivse 
skriiningu korral tehti diagnoosi täpsustamiseks ka muid biokeemilisi ja/või 
molekulaarseid analüüse.  
 Et välja selgitada KGH sagedaseima alatüübi PMM2-CDG eeldatav sagedus 
Eesti populatsioonis, analüüsiti Tartu Ülikooli Eesti Geenivaramu 2244 
geenidoonori PMM2 geeni andmeid. Arvutustes kasutati veidi muudetud Hardy-
Weinbergi seaduse matemaatilist väljundit. 
 Uurimustöö osana kirjeldati kahe patsiendi erinevaid KGH alatüüpe, mis 
diagnoositi positiivse skriiningu tulemusel. SLC35A2-CDG on küllaltki harva 
esinev KGH ning Eesti patsienti võrreldi 14 rahvusvahelise patsiendiga. Teisel 
patsiendil on tegemist uue, varem kirjeldamata KGH alatüübiga, mille põh-
juseks on tõenäoliselt STX5 geeni homosügootne mutatsioon. 
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Uuringu peamised tulemused ja järeldused 
1.  Esitasime kolme aasta jooksul teostatud KGH pilootskriiningu tulemused 
Eesti patsientide kohta. 
1.1  Transferriini IEF on lihtne ja tulemuslik meetod, et leida patsientidel N-
glükosüülimist mõjutavaid defekte. 
1.2  KGH kinnitus kuuel patsiendil 1230 skriinitust.  
1.3  Kõige sagedasem KGH alatüüp Eestis on sarnaselt teise riikidega 
PMM2-CDG. 
1.4  Parandasime oluliselt Eesti arstide hulgas teadlikkust KGH osas. 
2.  Hindasime kahest perekonnast pärit nelja Eesti PMM2-CDG diagnoosiga 
patsiendi fenotüüpi ja PMM2 geeni molekulaarseid muutusi. 
2.1  Eesti PMM2-CDG diagnoosiga patsientide fenotüüp sarnanes eelnevalt 
kirjeldatud patsientide fenotüübiga. 
2.2  Diagnoosisime PMM2-CDG ühe pere kolmel lapsel, kellel esineb 
haiguse kerge neuroloogiline fenotüüp ning normaalne-piiripealne 
kognitiivne areng, mida varasemalt on PMM2-CDG diagnoosiga pat-
sientidel harva kirjeldatud. 
2.3  PMM2-CDG diagnoosiga patsientide hulgas on kõige sagedasem 
PMM2 geenivariant p.Val131Met, mitte p.Arg141His nagu teistes 
populatsioonides. 
3. Esitasime andmed PMM2-CDG eeldatava sageduse ning levimuse kohta.  
3.1  Leidsime Tartu Ülikooli Eesti Geenivaramu geenidoonorite kogu 
genoomi sekveneerimise tulemustes viis erinevat PMM2 hetero-
sügootset mutatsiooni. Kõige sagedasem geenivariant on p.Arg141His 
kandlussagedusega 1/224; kandlussagedus geenivariandi p.Val131Met 
puhul on 1/449.  
3.2  Eeldatav PMM2-CDG sagedus Eestis on 1/77,000. Tartu Ülikooli Eesti 
Geenivaramu andmeid saab kasutada erinevate haiguste eeldatava 
sageduse hindamiseks.  
3.3  Eesti patsientide andmete põhjal on PMM2-CDG levimus laste hulgas 
1/79,000. 
4. Iseloomustasime SLC35A2-CDG fenotüüpi Eesti ja 14 rahvusvahelise 
patsiendi andmete põhjal. 
4.1  SLC35A2-CDG diagnoosimine on keeruline. Patsientidele on iseloo-
mulik mittespetsiifiline neuroloogiline haigus üldise arengu hilistumise, 
lihashüpotoonia, krampide ning epileptilise entsefalopaatiaga, aju MRT 
muutused (suur- ja väikeaju atroofia, hilinenud valgeaine müelini-
satsioon ja lühike mõhnkeha), düsmorfsed ilmingud ja lühike kasv. 
4.2  Negatiivne KGH skriining ei välista SLC35A2-CDG diagnoosi.  
4.3  Esitasime diagnostilise algoritmi hindamaks patsiente varasemalt kirjel-
damata SLC35A2 geenivariantidega ning negatiivse KGH skriininguga. 
Esmalt tuleks hinnata glükaane massispektromeetria meetodil. Kui 
glükaanide struktuur viitab glükosüülimishäirele, tuleks geenivariant 
lugeda haiguspõhjuslikuks. Kui glükaanide struktuur on normaalne, 
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tuleks patsientide kliinilisi tunnuseid kombineerida geenivariandi 
kahjulikkuse hindamisega, kasutades in silico arvutuslikke meetodeid.  
5.  Kirjeldasime uue, II tüüpi KGH-ga patsienti, kellel esinevat KGH alatüüpi 
põhjustab tõenäoliselt homosügootne geenivariatsioon STX5 geenis.  
5.1  Patsiendil olid multisüsteemsed KGH-le iseloomulikud sümptomid 
nagu düsmorfsus, maksafibroos  ja -puudulikkus, skeletianomaaliad 
(lühikesed jäsemed ja komppöiad), neeruanomaalia ning hüübimis- ja 
endokrinoloogilised häired.  
5.2  Viiendal elupäeval teostatud transferriini IEF viitas II tüüpi KGH 
defektile, mis arvati patsiendil esinenud sümptomite peamiseks põh-
juseks ning see võimaldas jätkata suunitletult täpsustavaid uuringud 
kinnitamaks KGH diagnoosi. 
5.3  Erinevate ülegenoomsete analüüside tulemusel leiti STX5 geenis 
homosügootne geenivariant, mis tõenäoliselt häirib Golgi kompleksi 
struktuuri ja funktsiooni ning seeläbi normaalse glükosüülimisprotsessi 
kulgemist.  
5.4  On väga tõenäoline, et leitud STX5 geenivariant on patogeenne. 
Funktsionaalsed uuringud jätkuvad. 
 
Antud uuring näitas, et KGH skriining on tulemuslik ning enamjaolt abistav 
vahend haiguste diagnostikas ja diferentsiaaldiagnostikas. Kahjuks ei saa 
välistada vale-negatiivseid ja –positiivseid vastuseid, näiteks tingituna patsiendi 
vanusest, KGH alatüübist, aga ka subjektiivsest hindamisest. Kuna osa KGH 
alatüüpe ei ole transferriini IEF-iga skriinitavad või tulemused võivad ajas 
muutuda, on oluline, et klinitsistid seda nüanssi silmas peaksid ning KGH 
kahtluse püsimisel uuringuid jätkaksid. 
 KGH skriining transferriini IEF-i meetodil on jätkunud SA TÜK ühendlabori 
kliinilise geneetika keskuse rutiinses töös ka pärast skriiningperioodi lõppu ning 
me oleme kahel patsiendil diagnoosinud KGH. 
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